pravastatin has been researched along with Cardiovascular Diseases in 222 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 23 (10.36) | 18.2507 |
| 2000's | 120 (54.05) | 29.6817 |
| 2010's | 68 (30.63) | 24.3611 |
| 2020's | 11 (4.95) | 2.80 |
| Authors | Studies |
|---|---|
| Aschenbrenner, DS | 1 |
| Chowdhury, EK; Curtis, AJ; Ernst, ME; McNeil, JJ; Murray, AM; Nelson, MR; Reid, CM; Ryan, J; Tonkin, AM; Wolfe, R; Woods, RL; Zhou, Z; Zoungas, S | 1 |
| Gussekloo, J; Jukema, JW; le Cessie, S; Marijt, KA; Mooijaart, SP; Rostamian, S; Trompet, S; van Buchem, MA; van Hall, T | 1 |
| Alkaabi, M; Amoodi, AA; Baraka, MA; Don, J; Elnour, AA; Farah, FH; Mazrouei, NA; Ramadan, A; Sadeq, A; Sam, KG | 1 |
| Nguyen, L; Pham, A; Polic, A; Thompson, JL | 1 |
| Chen, WM; Shia, BC; Wu, SY; Yu, JM | 1 |
| Adams, SP; Alaeiilkhchi, N; Tasnim, S; Wright, JM | 1 |
| Caspar, AT; Hemmer, S; Meyer, MR; Wagmann, L | 1 |
| Birukov, A; Dechend, R; Geisberger, S; Golic, M; Haase, N; Herse, F; Heuser, A; Kräker, K; Müller, DN; O'Driscoll, JM; Patey, O; Schütte, T; Thilaganathan, B; Verlohren, S | 1 |
| Hoang, T; Kim, J | 1 |
| Kang, HT; Kim, HS; Kim, J; Lee, JW; Yang, W | 1 |
| Blaum, CS; Davis, BR; Han, BH; Pervin, H; Piller, LB; Pressel, SL; Sutin, D; Williamson, JD | 1 |
| Burns, RB; Graham, K; Reynolds, EE; Sawhney, MS | 1 |
| Asselbergs, FW; Bakker, SJL; Dullaart, RPF; Eppinga, RN; Kofink, D; van der Harst, P; van Gilst, WH | 1 |
| Clark, JE; Garrett, N; Girardi, G; Pombo, J; Simmons, M; Umpierrez, M | 1 |
| Aschmann, HE; Puhan, MA; Yebyo, HG | 1 |
| Ala-Korpela, M; Boachie, C; Butterworth, A; Chen, Z; Clarke, R; Danesh, J; Davey Smith, G; Delles, C; Ford, I; Holmes, MV; Järvelin, MR; Jukema, JW; Kettunen, J; Lawlor, DA; Li, L; Lin, K; Männikkö, M; Millwood, IY; Perola, M; Rankin, N; Salomaa, V; Sattar, N; Sebert, S; Sliz, E; Trompet, S; Walters, R; Wang, Q; Welsh, P; Williams, CO; Würtz, P | 1 |
| Aschmann, HE; Kaufmann, M; Puhan, MA; Yebyo, HG | 1 |
| Betteridge, DJ; Carmena, R | 1 |
| de Haan, S; Ford, I; Jukema, JW; Rostamian, S; Sabayan, B; van Buchem, MA; van der Grond, J | 1 |
| Bae, J; Kryzhanovski, VA; LeNarz, LA; Sponseller, CA; Zhao, Z; Zhu, Y | 1 |
| de Craen, AJ; Ford, I; Jukema, JW; Lucke, J; Mooijaart, SP; Sattar, N; Stott, DJ; Trompet, S; Westendorp, RG | 1 |
| Nakagami, T; Nishimura, R; Sone, H; Tajima, N | 1 |
| Cagampang, FR; Elahi, MM; Hanson, MA; Ohri, SK | 1 |
| Camacho, X; Carter, AA; Gomes, T; Juurlink, DN; Mamdani, MM; Shah, BR | 1 |
| Fukui, K; Hibi, K; Kunishima, T; Michishita, I; Morino, Y; Nozue, T; Onishi, Y; Sozu, T; Takeyama, Y; Terashima, M; Tohyama, S; Umezawa, S; Yamamoto, S; Yamauchi, T | 1 |
| Cobbe, SM; Ford, I; Marchbank, L; McConnachie, A; Packard, CJ; Peacock, J; Robertson, M; Walker, A | 1 |
| Buckley, BM; de Craen, AJ; Ford, I; Jukema, JW; Sabayan, B; Sattar, N; van Buchem, MA; van der Grond, J; van Osch, MJ; Westendorp, RG | 1 |
| Angel-Zúñiga, JR; Cortés-Sanabria, L; Cueto-Manzano, AM; Martínez-Ramírez, HR; Ornelas-Carrillo, G; Rojas-Campos, E | 1 |
| Macchi, C; Magni, P; Morlotti, B; Ruscica, M; Sirtori, CR | 1 |
| Buckley, BM; de Craen, AJ; Devlin, JJ; Ford, I; Johnson, PC; Jukema, JW; Kearney, PM; Postmus, I; Sacks, FM; Sattar, N; Shiffman, D; Slagboom, PE; Stott, DJ; Trompet, S; Westendorp, RG | 1 |
| Díaz Rodríguez, Á | 1 |
| Flores-Le Roux, JA; Pedro-Botet, J | 1 |
| Mantilla, T | 1 |
| Hernández Mijares, A | 1 |
| Núñez-Cortés, JM | 1 |
| Pintó, X | 1 |
| Ebisawa, S; Ikeda, U; Izawa, A; Kagoshima, M; Kashima, Y; Kitabayashi, H; Koyama, J; Miura, T; Miyashita, Y; Sakurai, S; Tomita, T; Yamamoto, H | 1 |
| Dohi, T | 1 |
| Clarke, JT; Dimaio, C | 1 |
| Gouya, G; Herkner, H; Mesgarpour, B; Reichardt, B; Wolzt, M | 1 |
| de Craen, AJ; de Ruijter, W; Drewes, YM; Ford, I; Gussekloo, J; Jukema, JW; Mertens, BJ; Mooijaart, SP; Poortvliet, RK; Sattar, N; Stott, DJ; van Peet, PG; Wijsman, LW | 1 |
| Banach, M; Bittner, V; Hovingh, GK; Kastelein, JJ; Lip, GY; Mikhailidis, DP; Ray, K; Rysz, J; Sahebkar, A; Serban, C; Undas, A; Ursoniu, S; Watts, GF | 1 |
| Banefelt, J; Fox, KM; Gandra, SR; Hallberg, S; Johansson, G; Levin, LÅ; Mesterton, J; Sobocki, P | 1 |
| Ford, I; McCowan, C; Murray, H; Packard, CJ | 1 |
| de Craen, AJ; Ford, I; Jukema, JW; Mooijaart, SP; Muller, M; Sabayan, B; Sattar, N; Stott, DJ; Trompet, S; Welsh, P; Westendorp, RG; Wijsman, LW | 1 |
| de Craen, AJ; Lingsma, HF; Mooijaart, SP; Nieboer, D; Richard, E; Steyerberg, EW; van Leeuwen, N | 1 |
| de Craen, AJ; Jukema, JW; le Cessie, S; Sabayan, B; Smit, RA; Trompet, S; van Buchem, MA; van der Grond, J | 1 |
| Banach, M; Blaha, MJ; Chruściel, P; Jones, SR; Lip, GY; Martin, SS; Mikhailidis, DP; Mosteoru, S; Pencina, MJ; Ray, KK; Rembek-Wieliczko, M; Rysz, J; Sahebkar, A; Serban, MC; Toth, PP; Ursoniu, S | 1 |
| Aslangul, É; Assoumou, L; Bittar, R; Bonnefont-Rousselot, D; Cherfils, C; Costagliola, D; Federspiel, MC; Giral, P; Kalmykova, O; Valantin, MA | 1 |
| Chang, KC; Ko, NY; Li, CY; Ou, HT; Yang, CY | 1 |
| del Sol, AI; Nanayakkara, PW | 1 |
| Kurata, H; Kushiro, T; Mizuno, K; Nakamura, H; Nakaya, N; Ohashi, Y; Tajima, N; Teramoto, T; Uchiyama, S | 1 |
| Arora, P; Devereaux, PJ; Mills, EJ; Perri, D; Rachlis, B; Wu, P | 1 |
| Barnes, EH; Colquhoun, D; Keech, A; Nestel, P; Pollicino, C; Simes, J; Söderberg, S; Tonkin, AM; Yallop, J | 1 |
| Kushiro, T; Mizuno, K; Nakamura, H; Nakaya, N; Ohashi, Y; Tajima, N; Teramoto, T; Uchiyama, S | 2 |
| Bezlyak, V; Buckley, BM; de Craen, AJ; Ford, I; Jukema, JW; Packard, CJ; Perry, I; Sattar, N; Shepherd, J; Stott, DJ; Westendorp, RG | 1 |
| Lüscher, TF | 1 |
| Nakamura, H | 2 |
| Chan, ES; Mak, KH | 1 |
| Bhagavan, NV; Ha, CE; Ha, JS; Theriault, AG | 1 |
| Hirao, K; Mizuno, K; Nakamura, H; Ohashi, Y; Uchida, Y; Yoshida, T | 1 |
| Kassan, M; Montero, MJ; Sevilla, MA | 1 |
| Iwasaka, T; Kamihata, H; Manabe, K; Motohiro, M; Nakamura, S; Senoo, T; Sugiura, T; Yoshida, S | 1 |
| Arnesen, H; Lappegård, KT; Mollnes, TE; Seljeflot, I; Trøseid, M | 1 |
| Chayama, K; Fujii, Y; Higashi, Y; Imaizumi, T; Kihara, Y; Matsuoka, H; Soga, J; Sugano, R; Umei, H | 1 |
| Cannon, CP; Gibson, CM; Hochberg, CP; Pride, YB; Sabatine, MS; Sloan, S | 1 |
| Hickman, J | 1 |
| Nissen, SE | 1 |
| Mizuno, K; Nakamura, H; Nakaya, N; Ohashi, Y; Teramoto, T; Yokoyama, S | 1 |
| Fujioka, D; Hirano, M; Kawabata, K; Kitta, Y; Kobayashi, T; Kugiyama, K; Mishina, H; Nakamura, T; Obata, JE; Saito, Y; Sano, K; Watanabe, K; Watanabe, Y; Yano, T | 1 |
| Acharjee, S; Cannon, CP | 1 |
| Andrus, MR; East, J | 1 |
| Ishibashi, T | 1 |
| Császár, A; Farnier, M; Retterstøl, K; Steinmetz, A | 2 |
| Aslangul, E; Assoumou, LK; Bastard, JP; Capeau, J; Costagliola, D; Fellahi, S | 1 |
| Cannon, CP; De Lemos, JA; Morrow, DA; Ray, KK; Rifai, N; Sabatine, MS; Wilson, SR; Wiviott, SD; Zhou, S | 1 |
| Asselbergs, FW; Brouwers, FP; de Boer, RA; Gansevoort, RT; Hillege, HL; van Gilst, WH; van Veldhuisen, DJ | 1 |
| Nakagami, T; Nishimura, R; Ohashi, Y; Sone, H; Tajima, N | 1 |
| de Craen, AJ; Ford, I; Jukema, JW; McInnes, IB; Murray, HM; Packard, CJ; Sattar, N; Stott, DJ; Trompet, S; Welsh, P; Westendorp, RG | 1 |
| Hirahara, K; Mizuno, K; Mizutani, M; Nakamura, H; Nakaya, N; Ohashi, Y; Teramoto, T; Yokoyama, S | 1 |
| Aberg, JA; Evans, SE; Fichtenbaum, CJ | 1 |
| Kubota, Y; Mizuno, K; Nakamura, H; Nakaya, N; Ohashi, Y; Takahashi, S; Teramoto, T; Ueki, A; Yokoyama, S | 1 |
| Akao, H; Buckley, BM; de Craen, AJ; Ford, I; Jukema, JW; Kajinami, K; Packard, C; Polisecki, E; Robertson, M; Schaefer, EJ; Shepherd, J; Trompet, S; Westendorp, RG | 2 |
| Choudhury, RP; Iacob, AO | 1 |
| Arca, M; Budal, S; Degli Esposti, E; Degli Esposti, L; Sangiorgi, D; Vigna, GB | 1 |
| Ichikawa, S; Ishikura, N; Kamiyama, K; Matsushima, T; Mizuno, K; Nakamura, H; Nakaya, N; Ohashi, Y; Teramoto, T; Yokoyama, S | 1 |
| Farnier, M | 2 |
| Heintjes, EM; Herings, RM; Meerding, WJ; Penning-van Beest, FJ; Plat, AW; Sturkenboom, MC; Webb, K | 1 |
| Cobbe, S; Di Angelantonio, E; Doolin, O; Ford, I; Gudnason, V; Macfarlane, P; Packard, C; Sattar, N; Welsh, P; Willeit, P | 1 |
| Ayaori, M; Ikewaki, K; Ishikawa, T; Mizuno, K; Nakamura, H; Nishiwaki, M; Ohashi, Y; Ohsuzu, F | 1 |
| de Craen, AJ; de Ruijter, W; Ford, I; Gussekloo, J; Jukema, JW; Lloyd, SM; Mooijaart, SP; Packard, CJ; Poortvliet, RK; Sattar, N; Stott, DJ; Westendorp, RG | 1 |
| Gillies, C; Manktelow, B; Potter, JF | 1 |
| Armstrong, PW; Borer, J; Lorell, BH; Nissen, S | 1 |
| Liao, JK | 1 |
| Armitage, J; Collins, R | 1 |
| Pasternak, RC | 1 |
| Avorn, J; Benner, J; Ford, I; Ganz, DA; Gaw, A; Glynn, RJ; Jackson, J; Lagaay, AM; Schneeweiss, S; Walley, T; Wang, PS | 1 |
| Holme, I; Tonstad, S | 2 |
| Curhan, G; Kiberd, B; Moyé, L; Sacks, FM; Tonelli, M | 1 |
| Albert, MA; Glynn, RJ; Ridker, PM | 1 |
| Mascitelli, L; Pezzetta, F | 1 |
| Little, PJ | 1 |
| Kulbertus, H; Scheen, AJ | 1 |
| Forder, P; Hague, W; Hunt, D; Simes, J; Tonkin, A | 1 |
| Caro, J; Huybrechts, KF; Jackson, JD; Klittich, WS; McGuire, A | 1 |
| Arulchelvam, M; Baker, J; Beller, E; Best, J; Colquhoun, D; Hague, W; Hunt, D; Keech, A; Kirby, A; Simes, RJ; Tonkin, A | 1 |
| Braund, PS; Caslake, MJ; Cheng, S; Freeman, DJ; Gaffney, D; McMahon, AD; Packard, CJ; Samani, NJ; Wilson, V | 1 |
| Belder, R; Berry, DA; Berry, SM; Byington, RP; Fiedorek, FT; Ford, NF; Hennekens, CH; Jukema, JW; Natarajan, K; Pitt, B; Sacks, FM; Sheng-Lin, C; Tonkin, A; Walker, AJ | 1 |
| Hunt, D; Kirby, A; Liew, D; Magliano, D; Pater, H; Simes, J; Sundararajan, V; Tonkin, A | 1 |
| Ruef, J | 1 |
| Belder, R; Braunwald, E; Cannon, CP; Hill, KA; Joyal, SV; McCabe, CH; Pfeffer, MA; Rader, DJ; Rouleau, JL; Skene, AM | 1 |
| Topol, EJ | 1 |
| Fang, CH; Li, JJ | 1 |
| Boekholdt, SM; Hovingh, GK; Jukema, JW; Kastelein, JJ; Kuivenhoven, JA; van Tol, A | 1 |
| Pasternak, RC; Skerrett, PJ | 1 |
| Hegmann, T | 1 |
| LeLorier, J; Paradis, JM | 1 |
| Gotto, AM | 1 |
| Miller, M | 1 |
| Cobbe, SM; Craven, T; Curhan, GC; Furberg, C; Isles, C; Pfeffer, MA; Sacks, FM; Shepherd, J; Simes, J; Tonelli, M; Tonkin, A; West, M | 1 |
| von Schacky, C | 1 |
| Khush, KK; Waters, D | 1 |
| Asselbergs, FW; de Jong, PE; de Zeeuw, D; Diercks, GF; Hillege, HL; Janssen, WM; van Boven, AJ; van Gilst, WH; van Veldhuisen, DJ; Voors, AA | 1 |
| Arca, M; Boekholdt, SM; Cambien, F; de Grooth, GJ; Eiriksdottir, G; Freeman, DJ; Gudnason, V; Humphries, SE; Jukema, JW; Kakko, S; Kastelein, JJ; Kauma, H; Kuivenhoven, JA; Lanz, HJ; Liu, S; McMahon, AD; Miller, GJ; Montali, A; Nicaud, V; Sacks, FM; Savolainen, MJ; Shepherd, J; Talmud, PJ; Zwinderman, AH | 1 |
| Hirsch, M; Jones, P; O'Donnell, JC | 1 |
| Asselbergs, FW; Bakker, SJ; de Jong, PE; Geluk, CA; Hillege, HL; van Gilst, WH; Zijlstra, F | 1 |
| Brown, EA; Gaw, A; Murray, HM | 1 |
| Baghurst, K; Colquhoun, DM; Kirby, A; Mehalski, K; Nestel, PJ; Pollicino, C; Simes, RJ; Tonkin, AM; White, HD | 1 |
| Kastelein, JJ; van Leuven, SI | 1 |
| Auer, J; Eber, B; Lamm, G | 1 |
| Field, KM | 1 |
| Dieleman, JP; Dunselman, H; Straus, SM; Sturkenboom, MC; van Herpen, G; van Wijk, MA; van Wyk, JT | 1 |
| Colquhoun, D; Gay, CA; Nestel, P; Pollicino, C; Simes, J; Stocker, R; Sullivan, D; Tonkin, A; Whiting, M | 1 |
| Craven, T; Curhan, G; Furberg, C; Isles, C; Keech, A; Packard, C; Pfeffer, M; Sacks, F; Shepherd, J; Simes, J; Tonelli, M; Tonkin, A; West, M | 1 |
| Blauw, GJ; Bollen, EL; Buckley, BM; Cobbe, SM; Ford, I; Gaw, A; Hyland, M; Jukema, JW; Kamper, AM; Macfarlane, PW; Murphy, MB; Packard, CJ; Perry, IJ; Robertson, M; Shepherd, J; Stott, DJ; Sweeney, BJ; Twomey, C; Westendorp, RG | 1 |
| Hutten, BA; Kastelein, JJ; Koeijvoets, KC; Rodenburg, J; Sijbrands, EJ; Wiegman, A | 1 |
| Pilote, L; Rahme, E; Zhou, Z | 1 |
| Deray, G; Isnard-Bagnis, C; Karie, S; Launay-Vacher, V | 1 |
| Rosenson, RS | 1 |
| Blazing, M; Braunwald, E; Califf, R; Cannon, CP; de Lemos, JA; McCabe, CH; Murphy, SA; Wiviott, SD | 1 |
| Carr, A; Cooper, DA; Feneley, MP; Kent-Hughes, J; Kovacic, JC; Mallon, PW; Miller, J; Norris, R; Samaras, K | 1 |
| Boccara, F; Capeau, J; Gharakhanian, S | 1 |
| Hayashi, J; Maeda, S; Ohnishi, H; Okada, K; Sawayama, Y | 1 |
| Curhan, G; Jhangri, GS; Lopez-Jimenez, F; Pfeffer, M; Sacks, F; Tonelli, M | 1 |
| Asselbergs, FW; Atthobari, J; Boersma, C; de Jong, PE; de Jong-van den Berg, LT; de Vries, R; Gansevoort, RT; Hillege, HL; Postma, MJ; van Gilst, WH | 1 |
| Fiŝer, I; Kvas, E; Marschang, P; Patsch, JR; Ritsch, A; Sandhofer, A | 1 |
| Davidson, MH; Robinson, JG | 1 |
| Arakawa, K; Goto, Y; Itakura, H; Kitabatake, A; Mizuno, K; Muranaka, M; Nakamura, H; Nakaya, N; Nishimoto, S; Ohashi, Y; Toyota, T; Yamamoto, A | 1 |
| Vos, E | 1 |
| Nango, E; Saio, T; Yuasa, H | 1 |
| Gutkowski, K; Lubas, W | 1 |
| Blauw, GJ; Bollen, EL; Buckley, BM; Cobbe, SM; Ford, I; Gaw, A; Hyland, M; Jukema, JW; Kamper, AM; Macfarlane, PW; McConnachie, A; Murphy, MB; Murray, HM; Packard, CJ; Perry, IJ; Sattar, N; Shepherd, J; Stott, DJ; Sweeney, BJ; Twomey, C; Westendorp, RG | 1 |
| Coleman, CI; Dale, KM; Kluger, J; Patel, AA; Shah, SA; White, CM | 1 |
| Shepherd, J | 1 |
| Bhatt, DL; Brennan, DM; Fox, K; Mak, KH; Saw, J; Steinhubl, SR; Topol, EJ | 1 |
| Asselbergs, FW; Bakker, SJ; Hillege, HL; van der Harst, P; van Gilst, WH; van Veldhuisen, DJ; Voors, AA | 1 |
| Cappelleri, JC; Dubois, RW; Messerli, FH; Pinto, L; Sichrovsky, T; Tang, SS; Thakker, KM | 1 |
| Buckley, BM; de Craen, AJ; Ford, I; Jukema, JW; Maeda, N; McMahon, AD; Muallem, H; Ordovas, JM; Packard, C; Peter, I; Polisecki, E; Robertson, M; Schaefer, EJ; Shepherd, J; Westendorp, RG | 1 |
| Ellis, CJ; Hamer, AW | 1 |
| North, FM; Sharples, KJ; Simes, RJ; Stewart, RA; Tonkin, AM; White, HD | 1 |
| Pickering, TG | 1 |
| Gandhi, SK; Harley, CR; Heien, H; McDonough, K; Nelson, SP | 1 |
| Watson, KE | 1 |
| Criqui, MH; Dimsdale, JE; Golomb, BA; Ritchie, JB; White, HL | 1 |
| Doggrell, SA | 1 |
| Blauw, GJ; Buckley, BM; de Craen, AJ; Ford, I; Forouhi, NG; Freeman, DJ; Jukema, JW; Lennon, L; Macfarlane, PW; McConnachie, A; Murphy, MB; Packard, CJ; Sattar, N; Shaper, AG; Shepherd, J; Stott, DJ; Wannamethee, SG; Westendorp, RG; Whincup, PH | 1 |
| Sirtori, CR | 1 |
| Marx, HJ; Pearson, TA | 1 |
| Olsson, AG | 1 |
| Purcell, H | 1 |
| Masters, P; Shetty, A | 1 |
| Adkins, JC; Faulds, D | 1 |
| do Nascimento, LO; Maranhão e Pesquisadores, RC; Santos, RD | 1 |
| Danner, M; Hinzpeter, B; Lauterbach, KW; Tacke, J; Troche, CJ | 1 |
| Rosenson, RS; Tangney, CC | 1 |
| Pearson, TA | 1 |
| Albarrán, OG; García-Robles, R; Rábano, A; Ruilope, LM; Villa, E | 1 |
| Braunwald, E; Davis, BR; Glasser, SP; Grant, J; Johnstone, DE; Kell, S; Lewis, SJ; Limacher, M; Mitchell, J; Moye, LA; Pfeffer, MA; Sacks, FM; Timmis, G | 1 |
| Hingorani, AD; Vallance, P | 1 |
| Bottorff, MB; Cave, DG; Yenkowsky, JP | 1 |
| Caro, J; Ford, I; Klittich, W; McGuire, A; Norrie, J; Pettitt, D; Shepherd, J | 1 |
| Meyer, FP | 1 |
| Thomas, M | 1 |
| Bannerman, KS | 1 |
| Bero, L; Henry, D; Lee, K; Mah, C; Moynihan, R; Ross-Degnan, D; Soumerai, SB; Watkins, J | 1 |
| McNee, W | 1 |
| Smith, SC | 1 |
| Bak, AA; Crijns, HJ; de Jong, PE; Diercks, GF; Janssen, WM; van Boven, AJ; van Gilst, WH | 1 |
| Lauterbach, KW | 1 |
| Celesia, GG; Kellman, W; Ruosseau, P; Siegel, G; Wolozin, B | 1 |
| Durrington, P | 1 |
| Cobbe, S; Ford, I; Lowe, G; Macfarlane, P; Norrie, J; Packard, C; Rumley, A; Shepherd, J | 1 |
| Badimon, JJ; Chesebro, JH; Fallon, JT; Fuster, V; Harris, K; Harris, P; Jayaraman, S; Osende, JI; Rauch, U; Sandler, DA; Vorchheimer, DA | 1 |
| Moulin, P | 1 |
| Chiariello, M | 1 |
| Bouzamondo, A; Lechat, P; Sanchez, P; Sirol, M | 1 |
| Albert, MA; Danielson, E; Ridker, PM; Rifai, N | 1 |
| Simpson, RJ | 1 |
| Jackson, G | 1 |
| Le, NA | 1 |
| Faust, M; Kotzka, J; Krone, W; Müller-Wieland, D | 1 |
| Guijarro, C | 1 |
| Higashi, MK; Phillips, KA; Veenstra, DL | 1 |
| Ishikawa, T; Ito, H; Nakamura, H; Ohashi, Y; Orimo, H; Ouchi, Y; Saito, Y | 1 |
| Galloway, P; Greer, IA; Sattar, N | 1 |
| Asayama, J; Azuma, A; Nakagawa, M; Nakata, T; Sasaki, S; Sawada, S; Takeda, K | 1 |
| Braunwald, E; Byington, RP; Cobbe, SM; Davis, BR; Friedman, CP; Keech, A; Pfeffer, MA; Sacks, FM; Tonkin, A | 1 |
| Braunwald, E; Brown, LE; Cole, TG; Hamm, P; Hawkins, CM; Moye', L; Pfeffer, MA; Sacks, FM | 1 |
49 review(s) available for pravastatin and Cardiovascular Diseases
| Article | Year |
|---|---|
Association of cognitive function with increased risk of cancer death and all-cause mortality: Longitudinal analysis, systematic review, and meta-analysis of prospective observational studies.
Topics: Aged; Aged, 80 and over; Cardiovascular Diseases; Cognition; Cognitive Dysfunction; Female; Humans; Male; Neoplasms; Pravastatin; Prospective Studies | 2022 |
A Systematic Review of Randomized Clinical Trials on the Efficacy and Safety of Pitavastatin.
Topics: Atorvastatin; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Dyslipidemias; HIV Infections; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Metabolic Syndrome; Pravastatin; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Simvastatin | 2023 |
Statins in Pregnancy: Can We Justify Early Treatment of Reproductive Aged Women?
Topics: Adult; Atherosclerosis; Cardiovascular Diseases; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Infant, Newborn; Lactation; Pravastatin; Pregnancy | 2022 |
Pravastatin for lowering lipids.
Topics: Atorvastatin; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Drug-Related Side Effects and Adverse Reactions; Fluvastatin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Infant; Infant, Newborn; Pravastatin; Rosuvastatin Calcium | 2023 |
Comparative Effect of Statins and Omega-3 Supplementation on Cardiovascular Events: Meta-Analysis and Network Meta-Analysis of 63 Randomized Controlled Trials Including 264,516 Participants.
Topics: Aged; Atorvastatin; Cardiovascular Diseases; Coronary Disease; Dietary Supplements; Fatty Acids, Omega-3; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Network Meta-Analysis; Pravastatin; Randomized Controlled Trials as Topic; Stroke; Treatment Outcome | 2020 |
Comparative effectiveness and safety of statins as a class and of specific statins for primary prevention of cardiovascular disease: A systematic review, meta-analysis, and network meta-analysis of randomized trials with 94,283 participants.
Topics: Atorvastatin; Cardiovascular Diseases; Cause of Death; Chemical and Drug Induced Liver Injury; Double-Blind Method; Fluvastatin; Headache; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney Diseases; Lovastatin; Middle Aged; Muscular Diseases; Nausea; Neoplasms; Network Meta-Analysis; Placebos; Pravastatin; Randomized Controlled Trials as Topic; Risk Assessment; Rosuvastatin Calcium; Simvastatin; Withholding Treatment | 2019 |
Diabetogenic Action of Statins: Mechanisms.
Topics: Aged; Animals; Blood Glucose; Cardiovascular Diseases; Cholesterol; Diabetes Mellitus, Type 2; Humans; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Insulin; Male; Metabolic Syndrome; Mice; Middle Aged; Pravastatin; Quinolines; Risk Factors | 2019 |
Statin therapy and related risk of new-onset type 2 diabetes mellitus.
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pravastatin; Primary Prevention; Risk Assessment; Risk Factors; Secondary Prevention | 2014 |
[Combination of pravastatin and fenofibrate (Pravafenix ®). Safety studies].
Topics: Atherosclerosis; Cardiovascular Diseases; Drug Combinations; Fenofibrate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Lipids; Pravastatin; Risk Factors | 2014 |
The impact of statin therapy on plasma levels of von Willebrand factor antigen. Systematic review and meta-analysis of randomised placebo-controlled trials.
Topics: Adult; Aged; Antigens; Atherosclerosis; Atorvastatin; Cardiovascular Diseases; Fatty Acids, Monounsaturated; Female; Fluvastatin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Male; Middle Aged; Pravastatin; Randomized Controlled Trials as Topic; Regression Analysis; Risk Assessment; Rosuvastatin Calcium; Simvastatin; Thrombosis; von Willebrand Factor; Young Adult | 2016 |
Impact of statin therapy on plasma adiponectin concentrations: A systematic review and meta-analysis of 43 randomized controlled trial arms.
Topics: Adiponectin; Adult; Aged; Atorvastatin; Cardiovascular Diseases; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pravastatin; Quinolines; Randomized Controlled Trials as Topic; Regression Analysis; Rosuvastatin Calcium; Simvastatin | 2016 |
Pravastatin: an evidence-based statin?
Topics: Atherosclerosis; Cardiovascular Diseases; Evidence-Based Medicine; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Practice Guidelines as Topic; Pravastatin; Treatment Outcome | 2008 |
Primary prevention of cardiovascular mortality and events with statin treatments: a network meta-analysis involving more than 65,000 patients.
Topics: Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Confidence Intervals; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Risk | 2008 |
Office-based global cardiometabolic risk assessment: a simple tool incorporating nontraditional markers.
Topics: Atorvastatin; Biomarkers; Cardiovascular Diseases; Clinical Trials as Topic; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Hypertension; Male; Obesity; Office Visits; Practice Patterns, Physicians'; Pravastatin; Pyrroles; Risk Assessment; Smoking; United States | 2010 |
Use of statins in patients with chronic hepatitis C.
Topics: Adult; Cardiovascular Diseases; Contraindications; Hepatitis C; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver; Liver Function Tests; Pravastatin; Transaminases | 2010 |
[Anti-atherosclerotic and anti-inflammatory effects of statin on cardiovascular disease and their mechanisms].
Topics: Animals; Atherosclerosis; Cardiovascular Diseases; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Mevalonic Acid; Monomeric GTP-Binding Proteins; Plaque, Atherosclerotic; Pravastatin; Primary Prevention; Randomized Controlled Trials as Topic; Secondary Prevention | 2011 |
Targeting HDL-cholesterol to reduce residual cardiovascular risk.
Topics: Atorvastatin; Cardiovascular Diseases; Cholesterol, HDL; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Pravastatin; Pyrimidines; Pyrroles; Risk Factors; Rosuvastatin Calcium; Sulfonamides | 2012 |
Pravastatin and fenofibrate in combination (Pravafenix(®)) for the treatment of high-risk patients with mixed hyperlipidemia.
Topics: Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Drug Combinations; Fenofibrate; Humans; Hyperlipidemias; Hypolipidemic Agents; Pravastatin; Risk Factors; Triglycerides | 2012 |
Interventions in the management of serum lipids for preventing stroke recurrence.
Topics: Cardiovascular Diseases; Clofibrate; Estrogens, Conjugated (USP); Humans; Hypolipidemic Agents; Pravastatin; Recurrence; Stroke | 2002 |
Beyond lipid lowering: the role of statins in vascular protection.
Topics: Animals; Cardiovascular Diseases; Coronary Artery Disease; Endothelium, Vascular; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Neovascularization, Physiologic; Pravastatin; Randomized Controlled Trials as Topic; Simvastatin; Stroke | 2002 |
Effect of pravastatin on cardiovascular events and mortality in 1516 women with coronary heart disease: results from the Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) study.
Topics: Adult; Age Factors; Aged; Anticholesteremic Agents; Cardiovascular Diseases; Cause of Death; Coronary Disease; Female; Hospitalization; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Male; Middle Aged; Patient Compliance; Pravastatin; Recurrence; Risk Factors; Safety; Sex Factors; Treatment Outcome | 2003 |
Additive benefits of pravastatin and aspirin to decrease risks of cardiovascular disease: randomized and observational comparisons of secondary prevention trials and their meta-analyses.
Topics: Aged; Anticholesteremic Agents; Aspirin; Cardiovascular Diseases; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Multivariate Analysis; Platelet Aggregation Inhibitors; Pravastatin; Randomized Controlled Trials as Topic; Risk Factors; Stroke | 2004 |
[Treatment with statins of the elderly].
Topics: Aged; Aged, 80 and over; Anticholesteremic Agents; Cardiovascular Diseases; Cohort Studies; Humans; Pravastatin; Prospective Studies; Risk Factors | 2004 |
[Interactions of statins with antithrombotic drugs].
Topics: Animals; Anticholesteremic Agents; Aspirin; Atorvastatin; Cardiovascular Diseases; Clopidogrel; Controlled Clinical Trials as Topic; Drug Interactions; Drug Therapy, Combination; Fibrinolytic Agents; Follow-Up Studies; Hemostasis; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Platelet Aggregation Inhibitors; Pravastatin; Primary Prevention; Pyrroles; Rats; Ticlopidine; Time Factors | 2004 |
CETP gene variation: relation to lipid parameters and cardiovascular risk.
Topics: Cardiovascular Diseases; Carrier Proteins; Cholesterol; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Coronary Vessels; Genetic Variation; Genotype; Glycoproteins; Humans; Lipid Metabolism; Lipoproteins, HDL; Mutation; Pravastatin | 2004 |
ALLHAT-LLT: questions, questions, and more questions (and some answers).
Topics: Aged; Cardiovascular Diseases; Cholesterol, LDL; Clinical Trials as Topic; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypertension; Male; Middle Aged; Pravastatin; Risk | 2004 |
Effect of pravastatin on cardiovascular events in people with chronic kidney disease.
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Cardiovascular Diseases; Chronic Disease; Comorbidity; Coronary Disease; Creatinine; Databases, Factual; Double-Blind Method; Drug Evaluation; Female; Glomerular Filtration Rate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Kidney Diseases; Male; Middle Aged; Myocardial Infarction; Myocardial Revascularization; Pravastatin; Randomized Controlled Trials as Topic; Risk | 2004 |
Cholesteryl ester transfer protein TaqIB variant, high-density lipoprotein cholesterol levels, cardiovascular risk, and efficacy of pravastatin treatment: individual patient meta-analysis of 13,677 subjects.
Topics: Cardiovascular Diseases; Carrier Proteins; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Glycoproteins; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Polymorphism, Genetic; Pravastatin; Randomized Controlled Trials as Topic; Regression Analysis; Risk; Taq Polymerase | 2005 |
Atorvastatin.
Topics: Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Cardiovascular Diseases; Carotid Arteries; Cholesterol, LDL; Coronary Artery Disease; Drug Interactions; Endothelium, Vascular; Forecasting; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Leukocytes; Pravastatin; Proportional Hazards Models; Pyrroles; Randomized Controlled Trials as Topic | 2005 |
Effect of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors on high-sensitivity C-reactive protein levels.
Topics: Animals; Atherosclerosis; Atorvastatin; C-Reactive Protein; Cardiovascular Diseases; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Metabolic Syndrome; Pravastatin; Pyrroles; Risk Factors; Simvastatin | 2005 |
Are statins created equal? Evidence from randomized trials of pravastatin, simvastatin, and atorvastatin for cardiovascular disease prevention.
Topics: Atorvastatin; Cardiovascular Diseases; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Simvastatin; Therapeutic Equivalency; Treatment Outcome | 2006 |
[Statins in patients with kidney failure: efficacy, tolerance, and prescription guidelines in patients with chronic kidney disease and renal transplant].
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Cholesterol; Cholesterol, LDL; Dyslipidemias; Fatty Acids, Monounsaturated; Fluorobenzenes; Fluvastatin; Graft Rejection; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Indoles; Kidney Failure, Chronic; Liver Transplantation; Middle Aged; Pravastatin; Primary Prevention; Prospective Studies; Proteinuria; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Renal Dialysis; Risk Factors; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Time Factors | 2006 |
Combination therapy with ezetimibe and simvastatin to achieve aggressive LDL reduction.
Topics: Anticholesteremic Agents; Atorvastatin; Azetidines; C-Reactive Protein; Cardiovascular Diseases; Drug Therapy, Combination; Ezetimibe; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Intestinal Absorption; Lipoproteins, LDL; Phytosterols; Pravastatin; Pyrroles; Simvastatin | 2006 |
[C-reactive protein in cardiovascular diseases].
Topics: Algorithms; Biomarkers; C-Reactive Protein; Cardiovascular Diseases; Coronary Artery Disease; Humans; Inflammation; Inflammation Mediators; Pravastatin; Predictive Value of Tests; Risk Factors; Sensitivity and Specificity | 2006 |
Impact of gender on statin efficacy.
Topics: Age Distribution; Aged; Cardiovascular Diseases; Comorbidity; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Incidence; Male; Middle Aged; Odds Ratio; Pravastatin; Probability; Prognosis; Randomized Controlled Trials as Topic; Regression Analysis; Risk Assessment; Severity of Illness Index; Sex Distribution; Simvastatin; Survival Analysis; Treatment Outcome | 2007 |
Impact of systemic hypertension on the cardiovascular benefits of statin therapy--a meta-analysis.
Topics: Aged; Atorvastatin; Cardiovascular Diseases; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Indoles; Male; Middle Aged; Pravastatin; Prognosis; Pyrroles; Randomized Controlled Trials as Topic; Simvastatin; Therapeutics | 2008 |
What is the evidence in favor of low-dose statin therapy in 2008?
Topics: Cardiovascular Diseases; Disease Progression; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pravastatin; Risk Assessment; Simvastatin; Treatment Outcome | 2008 |
Is atorvastatin superior to other statins? Analysis of the clinical trials with atorvastatin having cardiovascular endpoints.
Topics: Amlodipine; Anticholesteremic Agents; Atorvastatin; Azetidines; Cardiovascular Diseases; Clinical Trials as Topic; Clofibric Acid; Ezetimibe; Fatty Acids, Monounsaturated; Fluorobenzenes; Fluvastatin; Heptanoic Acids; Humans; Indoles; Pravastatin; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2006 |
Tissue selectivity of hydroxymethylglutaryl coenzyme A (HMG CoA) reductase inhibitors.
Topics: Animals; Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol; Humans; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Pravastatin; Rhabdomyolysis; Risk Factors; Simvastatin; Species Specificity; Structure-Activity Relationship; Tissue Distribution | 1993 |
Micronised fenofibrate: a review of its pharmacodynamic properties and clinical efficacy in the management of dyslipidaemia.
Topics: Cardiovascular Diseases; Cholesterol; Cholesterol, HDL; Clinical Trials as Topic; Controlled Clinical Trials as Topic; Diabetes Complications; Dose-Response Relationship, Drug; Drug Delivery Systems; Drug Tolerance; Fenofibrate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Lipoproteins, LDL; Pravastatin; Simvastatin | 1997 |
Cost-effectiveness of primary and secondary prevention in cardiovascular diseases.
Topics: Cardiovascular Diseases; Cost-Benefit Analysis; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pravastatin; Quality-Adjusted Life Years; Risk Assessment; Risk Factors; Simvastatin | 1998 |
Antiatherothrombotic properties of statins: implications for cardiovascular event reduction.
Topics: Animals; Antithrombins; Cardiovascular Diseases; Cholesterol, LDL; Clinical Trials as Topic; Coronary Disease; Endothelium, Vascular; Fibrinogen; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Inflammation; Lovastatin; Muscle, Smooth, Vascular; Platelet Aggregation; Pravastatin; Simvastatin; Thromboplastin; Thrombosis | 1998 |
[The hyperlipidemias. Role of various statins].
Topics: Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Indoles; Lovastatin; Pravastatin; Pyridines; Pyrroles; Simvastatin | 1999 |
Bridging the treatment gap.
Topics: Adult; Anticholesteremic Agents; Cardiovascular Diseases; Coronary Disease; Female; Humans; Hypercholesterolemia; Lovastatin; Male; Middle Aged; Pravastatin; Risk Factors; Self Medication; Simvastatin; United States | 2000 |
[Statins and cardiovascular disease prevention: use and prospective].
Topics: Aged; Anticholesteremic Agents; Cardiovascular Diseases; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Pravastatin | 2000 |
[Treatment with statins for the reduction of cardiovascular risk].
Topics: Anticholesteremic Agents; Cardiovascular Diseases; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pravastatin; Risk Factors; Simvastatin | 2001 |
[Does statin therapy reduce the risk of stroke? A meta-analysis].
Topics: Age Distribution; Cardiovascular Diseases; Cause of Death; Effect Modifier, Epidemiologic; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Pravastatin; Primary Prevention; Risk; Risk Factors; Simvastatin; Stroke; Survival Analysis; Treatment Outcome | 2001 |
[Cholesterin synthase inhibition and atherosclerosis].
Topics: Animals; Arteriosclerosis; Cardiovascular Diseases; CCAAT-Enhancer-Binding Proteins; Cholesterol; Cholesterol, LDL; Coenzyme A Ligases; Diabetes Mellitus, Type 2; DNA-Binding Proteins; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hydroxymethylglutaryl-CoA Synthase; Hyperlipidemias; Pravastatin; Pyridines; Randomized Controlled Trials as Topic; Sterol Regulatory Element Binding Protein 1; Transcription Factors | 2001 |
Statins as novel therapies for osteoporosis?
Topics: Cardiovascular Diseases; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Osteoporosis, Postmenopausal; Pravastatin | 2002 |
72 trial(s) available for pravastatin and Cardiovascular Diseases
| Article | Year |
|---|---|
Comparison of statins for primary prevention of cardiovascular disease and persistent physical disability in older adults.
Topics: Aged; Aged, 80 and over; Atorvastatin; Cardiovascular Diseases; Disabled Persons; Double-Blind Method; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Pravastatin; Primary Prevention; Proportional Hazards Models; Rosuvastatin Calcium; Simvastatin | 2022 |
Effect of Statin Treatment vs Usual Care on Primary Cardiovascular Prevention Among Older Adults: The ALLHAT-LLT Randomized Clinical Trial.
Topics: Aged; Antihypertensive Agents; Cardiovascular Diseases; Cholesterol, LDL; Drug Monitoring; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypertension; Male; Medication Therapy Management; Outcome and Process Assessment, Health Care; Pravastatin; Primary Prevention; United States | 2017 |
Statin Effects on Metabolic Profiles: Data From the PREVEND IT (Prevention of Renal and Vascular End-stage Disease Intervention Trial).
Topics: Adult; Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol, LDL; Fatty Acids; Female; Humans; Lipid Metabolism; Male; Metabolome; Metabolomics; Middle Aged; Pravastatin; Time Factors | 2017 |
Metabolomic consequences of genetic inhibition of PCSK9 compared with statin treatment.
Topics: Aged; Aged, 80 and over; Amino Acids; Cardiovascular Diseases; Cholesterol, LDL; Cholesterol, VLDL; Double-Blind Method; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Mendelian Randomization Analysis; Metabolomics; PCSK9 Inhibitors; Placebo Effect; Pravastatin; Proprotein Convertase 9 | 2018 |
Cognitive Function in Dementia-Free Subjects and Survival in Old Age: The PROSPER Study.
Topics: Aged; Aged, 80 and over; Cardiovascular Diseases; Cause of Death; Cerebrovascular Circulation; Cognition; Dementia; Executive Function; Female; Geriatric Assessment; Humans; Internationality; Magnetic Resonance Imaging; Male; Memory; Multivariate Analysis; Neuropsychological Tests; Pravastatin; Proportional Hazards Models; Prospective Studies; Survival Analysis | 2019 |
Circulating interleukin-6 concentration and cognitive decline in old age: the PROSPER study.
Topics: Aged; Aged, 80 and over; Cardiovascular Diseases; Cognition; Cognition Disorders; Confounding Factors, Epidemiologic; Cross-Sectional Studies; Executive Function; Female; Follow-Up Studies; Genotype; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Inflammation; Interleukin-6; Ireland; Male; Netherlands; Neuropsychological Tests; Polymorphism, Single Nucleotide; Pravastatin; Promoter Regions, Genetic; Risk Assessment; Risk Factors; Scotland; Stroke | 2013 |
Importance of high-density lipoprotein cholesterol control during pravastatin treatment in hypercholesterolemic Japanese with type 2 diabetes mellitus: a post hoc analysis of MEGA study.
Topics: Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Pravastatin | 2013 |
C-reactive protein and future cardiovascular events in statin-treated patients with angina pectoris: the extended TRUTH study.
Topics: Aged; Angina Pectoris; C-Reactive Protein; Cardiovascular Diseases; Coronary Artery Disease; Female; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Ischemia; Japan; Male; Middle Aged; Myocardial Infarction; Plaque, Atherosclerotic; Pravastatin; Prospective Studies; Quinolines; Regression Analysis; Risk Factors; Treatment Outcome; Ultrasonography, Interventional | 2013 |
Long-term impact on healthcare resource utilization of statin treatment, and its cost effectiveness in the primary prevention of cardiovascular disease: a record linkage study.
Topics: Cardiovascular Diseases; Cost-Benefit Analysis; Health Resources; Hospitalization; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Pravastatin; Primary Prevention; Quality-Adjusted Life Years; State Medicine; Stroke; Treatment Outcome | 2014 |
Total cerebral blood flow and mortality in old age: a 12-year follow-up study.
Topics: Aged; Aged, 80 and over; Anticholesteremic Agents; Brain; Cardiovascular Diseases; Cerebrovascular Circulation; Chi-Square Distribution; Female; Humans; Image Processing, Computer-Assisted; Longitudinal Studies; Magnetic Resonance Imaging; Male; Pravastatin; Risk Factors | 2013 |
Anti-inflammatory interventions in end-stage kidney disease: a randomized, double-blinded, controlled and crossover clinical trial on the use of pravastatin in continuous ambulatory peritoneal dialysis.
Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; C-Reactive Protein; Cardiovascular Diseases; Cholesterol, LDL; Cross-Over Studies; Double-Blind Method; Female; Humans; Inflammation; Kidney Failure, Chronic; Male; Mexico; Middle Aged; Peritoneal Dialysis, Continuous Ambulatory; Placebos; Pravastatin; Treatment Outcome; Young Adult | 2013 |
In search for genetic determinants of clinically meaningful differential cardiovascular event reduction by pravastatin in the PHArmacogenetic study of Statins in the Elderly at risk (PHASE)/PROSPER study.
Topics: Aged; Aged, 80 and over; Blood Pressure; Cardiovascular Diseases; Female; Follow-Up Studies; Genetic Variation; Genome-Wide Association Study; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; International Cooperation; Male; Polymorphism, Single Nucleotide; Pravastatin; Prospective Studies; Regression Analysis | 2014 |
Assessment of lipophilic vs. hydrophilic statin therapy in acute myocardial infarction – ALPS-AMI study.
Topics: Aged; Atorvastatin; Cardiovascular Diseases; Cholesterol; Cholesterol, LDL; Female; Glycated Hemoglobin; Heart Failure; Hospitalization; Humans; Hydrophobic and Hydrophilic Interactions; Hypercholesterolemia; Japan; Kaplan-Meier Estimate; Lipids; Male; Middle Aged; Mortality; Myocardial Infarction; Myocardial Revascularization; Patient Acceptance of Health Care; Pravastatin; Recurrence; Single-Blind Method; Solubility | 2015 |
Risk stratification and treatment effect of statins in secondary cardiovascular prevention in old age: Additive value of N-terminal pro-B-type natriuretic peptide.
Topics: Age Factors; Aged; Aged, 80 and over; Biomarkers; Cardiovascular Diseases; Double-Blind Method; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Natriuretic Peptide, Brain; Netherlands; Peptide Fragments; Pravastatin; Prognosis; Prospective Studies; Recurrence; Risk Assessment; Risk Factors; Secondary Prevention | 2016 |
High-sensitivity cardiac troponin T is associated with cognitive decline in older adults at high cardiovascular risk.
Topics: Aged; Biomarkers; Cardiovascular Diseases; Cognition; Cognitive Dysfunction; Double-Blind Method; Female; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Pravastatin; Prognosis; Prospective Studies; Risk Factors; Troponin T | 2016 |
Higher Visit-to-Visit Low-Density Lipoprotein Cholesterol Variability Is Associated With Lower Cognitive Performance, Lower Cerebral Blood Flow, and Greater White Matter Hyperintensity Load in Older Subjects.
Topics: Aged; Attention; Cardiovascular Diseases; Cerebrovascular Circulation; Cholesterol, LDL; Cognition Disorders; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Magnetic Resonance Imaging; Male; Mental Recall; Pravastatin; Prognosis; Socioeconomic Factors; White Matter | 2016 |
Leptin, but not adiponectin, is a predictor of recurrent cardiovascular events in men: results from the LIPID study.
Topics: Adiponectin; Aged; Biomarkers; Cardiovascular Diseases; Case-Control Studies; Coronary Disease; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Leptin; Logistic Models; Longitudinal Studies; Male; Middle Aged; Myocardial Infarction; Natriuretic Peptide, Brain; Peptide Fragments; Pravastatin; Recurrence; Risk; Stroke | 2009 |
Pravastatin for cardiovascular event primary prevention in patients with mild-to-moderate hypertension in the Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese (MEGA) Study.
Topics: Aged; Anticholesteremic Agents; Blood Pressure; Cardiovascular Diseases; Cerebral Infarction; Cholesterol; Combined Modality Therapy; Coronary Disease; Diet; Dyslipidemias; Female; Follow-Up Studies; Humans; Hypertension; Incidence; Japan; Male; Middle Aged; Pravastatin; Severity of Illness Index | 2009 |
[Primary prevention trial by lowering hyperlipidemia on the cardiovascular disease (MEGA Study)].
Topics: Adult; Aged; Anticholesteremic Agents; Cardiovascular Diseases; Female; Humans; Hypercholesterolemia; Male; Middle Aged; Pravastatin | 2009 |
Pravastatin and cardiovascular risk in moderate chronic kidney disease.
Topics: Adult; Aged; Cardiovascular Diseases; Female; Glomerular Filtration Rate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Japan; Kidney Failure, Chronic; Male; Middle Aged; Pravastatin; Risk | 2009 |
The effect of exercise on serum levels of interleukin-18 and components of the metabolic syndrome.
Topics: Adult; Cardiovascular Diseases; Combined Modality Therapy; Exercise Therapy; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation Mediators; Interleukin-18; Male; Metabolic Syndrome; Middle Aged; Pravastatin | 2009 |
Endothelial function in subjects with isolated low HDL cholesterol: role of nitric oxide and circulating progenitor cells.
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Cardiovascular Diseases; Case-Control Studies; Cholesterol, HDL; Cohort Studies; Endothelium, Vascular; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Nitric Oxide; Nitroglycerin; Pravastatin; Reference Values; Risk Factors; Statistics, Nonparametric; Stem Cells; Vascular Endothelial Growth Factor A; Vasodilation; Vasodilator Agents; Young Adult | 2010 |
Effect of intensive statin therapy on clinical outcomes among patients undergoing percutaneous coronary intervention for acute coronary syndrome. PCI-PROVE IT: A PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis I
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Atorvastatin; Cardiovascular Diseases; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pravastatin; Pyrroles | 2009 |
Association between lowering low-density lipoprotein cholesterol with pravastatin and primary prevention of cardiovascular disease in mild to moderate hypercholesterolemic Japanese.
Topics: Adult; Aged; Asian People; Cardiovascular Diseases; Cholesterol, LDL; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Pravastatin; Risk Factors; Treatment Outcome | 2010 |
Comparative study of bezafibrate and pravastatin in patients with coronary artery disease and high levels of remnant lipoprotein.
Topics: Aged; Anticholesteremic Agents; Bezafibrate; Cardiovascular Diseases; Cholesterol; Coronary Artery Disease; Female; Follow-Up Studies; Humans; Hypolipidemic Agents; Lipids; Lipoproteins; Male; Middle Aged; Pravastatin; Triglycerides | 2010 |
Fixed-dose combination fenofibrate/pravastatin 160/40 mg versus simvastatin 20 mg monotherapy in adults with type 2 diabetes and mixed hyperlipidemia uncontrolled with simvastatin 20 mg: a double-blind, randomized comparative study.
Topics: Aged; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Combinations; Female; Fenofibrate; Follow-Up Studies; Humans; Hyperlipidemias; Hypolipidemic Agents; Male; Middle Aged; Pravastatin; Simvastatin | 2011 |
Assessment of adiponectin and the risk of recurrent cardiovascular events in patients presenting with an acute coronary syndrome: observations from the Pravastatin Or atorVastatin Evaluation and Infection Trial-Thrombolysis in Myocardial Infarction 22 (PR
Topics: Acute Coronary Syndrome; Adiponectin; Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Female; Heart Failure; Heptanoic Acids; Humans; Male; Middle Aged; Myocardial Infarction; Pravastatin; Pyrroles; Recurrence; Risk Assessment | 2011 |
Long-term effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria:Ten years of follow-up of Prevention of Renal and Vascular End-stage Disease Intervention Trial (PREVEND IT).
Topics: Adult; Aged; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Anticholesteremic Agents; Cardiovascular Diseases; Female; Follow-Up Studies; Fosinopril; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pravastatin | 2011 |
Relationship between hemoglobin A1c and cardiovascular disease in mild-to-moderate hypercholesterolemic Japanese individuals: subanalysis of a large-scale randomized controlled trial.
Topics: Adult; Aged; Anticholesteremic Agents; Cardiovascular Diseases; Diet Therapy; Female; Follow-Up Studies; Glycated Hemoglobin; Humans; Hypercholesterolemia; Incidence; Japan; Lipids; Male; Middle Aged; Pravastatin; Risk Factors; Severity of Illness Index | 2011 |
Circulating interleukin-10 and risk of cardiovascular events: a prospective study in the elderly at risk.
Topics: Age Factors; Aged; Aged, 80 and over; Aging; Biomarkers; Cardiovascular Diseases; Case-Control Studies; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Interleukin-10; Logistic Models; Male; Odds Ratio; Pravastatin; Proportional Hazards Models; Prospective Studies; Risk Assessment; Risk Factors; Time Factors | 2011 |
Low-dose pravastatin and age-related differences in risk factors for cardiovascular disease in hypercholesterolaemic Japanese: analysis of the management of elevated cholesterol in the primary prevention group of adult Japanese (MEGA study).
Topics: Adult; Age Factors; Aged; Asian People; Cardiovascular Diseases; Cholesterol; Coronary Disease; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Hypercholesterolemia; Male; Middle Aged; Pravastatin; Risk Factors; Stroke | 2011 |
Usefulness of LDL-C-related parameters to predict cardiovascular risk and effect of pravastatin in mild-to-moderate hypercholesterolemia.
Topics: Adult; Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol, LDL; Female; Humans; Hypercholesterolemia; Male; Middle Aged; Pravastatin; Prospective Studies; Risk Factors; ROC Curve; Young Adult | 2012 |
Genetic variation at the SLCO1B1 gene locus and low density lipoprotein cholesterol lowering response to pravastatin in the elderly.
Topics: Age Factors; Aged; Aged, 80 and over; Analysis of Variance; Biomarkers; Cardiovascular Diseases; Chi-Square Distribution; Cholesterol, LDL; Europe; Female; Heterozygote; Homozygote; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Linkage Disequilibrium; Liver X Receptors; Liver-Specific Organic Anion Transporter 1; Logistic Models; Male; Organic Anion Transporters; Orphan Nuclear Receptors; Phenotype; Polymorphism, Single Nucleotide; Pravastatin; Prospective Studies; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome | 2012 |
KIF6, LPA, TAS2R50, and VAMP8 genetic variation, low density lipoprotein cholesterol lowering response to pravastatin, and heart disease risk reduction in the elderly.
Topics: Age Factors; Aged; Aged, 80 and over; Analysis of Variance; Cardiovascular Diseases; Chi-Square Distribution; Cholesterol, LDL; Europe; Female; Homozygote; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Kinesins; Linkage Disequilibrium; Lipoprotein(a); Male; Phenotype; Polymorphism, Single Nucleotide; Pravastatin; Prospective Studies; R-SNARE Proteins; Receptors, G-Protein-Coupled; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome | 2012 |
Comparative efficacy and safety of fenofibrate/pravastatin plus ezetimibe triple therapy and simvastatin/ezetimibe dual therapy in type 2 diabetic patients with mixed hyperlipidaemia and cardiovascular disease.
Topics: Aged; Azetidines; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Combinations; Drug Therapy, Combination; Ezetimibe; Female; Fenofibrate; Humans; Hyperlipidemias; Hypolipidemic Agents; Male; Middle Aged; Pravastatin; Simvastatin; Treatment Outcome | 2012 |
The effect of low-dose pravastatin in metabolic syndrome for primary prevention of cardiovascular disease in Japan: a post hoc analysis of the MEGA study.
Topics: Adult; Aged; Anticholesteremic Agents; Cardiovascular Diseases; Combined Modality Therapy; Coronary Disease; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Japan; Male; Metabolic Syndrome; Middle Aged; Pravastatin; Primary Prevention | 2012 |
Blood pressure variability and cardiovascular risk in the PROspective Study of Pravastatin in the Elderly at Risk (PROSPER).
Topics: Aged; Aged, 80 and over; Blood Pressure; Cardiovascular Diseases; Diastole; Female; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Pravastatin; Proportional Hazards Models; Prospective Studies; Risk Factors; Systole | 2012 |
Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT).
Topics: Aged; Anticholesteremic Agents; Cardiovascular Diseases; Cause of Death; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypertension; Lipids; Male; Middle Aged; Pravastatin; Proportional Hazards Models; Risk Factors | 2002 |
Pravastatin for secondary prevention of cardiovascular events in persons with mild chronic renal insufficiency.
Topics: Aged; Cardiovascular Diseases; Creatinine; Double-Blind Method; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Kidney Failure, Chronic; Male; Middle Aged; Patient Compliance; Pravastatin; Stroke | 2003 |
Alcohol consumption and plasma concentration of C-reactive protein.
Topics: Alcohol Drinking; C-Reactive Protein; Cardiovascular Diseases; Cross-Sectional Studies; Ethanol; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Lipids; Male; Middle Aged; Pravastatin; Risk Factors | 2003 |
[Clinical study of the month. The ALLHAT-LLT trial].
Topics: Aged; Anticholesteremic Agents; Cardiovascular Diseases; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypertension; Male; Pravastatin; Randomized Controlled Trials as Topic; Risk Factors | 2003 |
Effect of pravastatin on cardiovascular events and mortality in 1516 women with coronary heart disease: results from the Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) study.
Topics: Adult; Age Factors; Aged; Anticholesteremic Agents; Cardiovascular Diseases; Cause of Death; Coronary Disease; Female; Hospitalization; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Male; Middle Aged; Patient Compliance; Pravastatin; Recurrence; Risk Factors; Safety; Sex Factors; Treatment Outcome | 2003 |
Secondary prevention of cardiovascular events with long-term pravastatin in patients with diabetes or impaired fasting glucose: results from the LIPID trial.
Topics: Adult; Aged; Angina, Unstable; Anticholesteremic Agents; Blood Glucose; Cardiovascular Diseases; Coronary Artery Disease; Coronary Restenosis; Diabetes Mellitus, Type 2; Fasting; Female; Follow-Up Studies; Glucose Intolerance; Humans; Hyperlipidemias; Male; Middle Aged; Myocardial Infarction; Pravastatin; Risk Factors; Stroke; Treatment Outcome | 2003 |
Intensive versus moderate lipid lowering with statins after acute coronary syndromes.
Topics: Angina, Unstable; Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Pravastatin; Proportional Hazards Models; Pyrroles | 2004 |
Effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria.
Topics: Adult; Aged; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Cardiovascular Diseases; Cohort Studies; Double-Blind Method; Female; Follow-Up Studies; Fosinopril; Hospitalization; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Life Tables; Male; Middle Aged; Pravastatin; Treatment Outcome | 2004 |
Rosuvastatin is cost-effective in treating patients to low-density lipoprotein-cholesterol goals compared with atorvastatin, pravastatin and simvastatin: analysis of the STELLAR trial.
Topics: Atorvastatin; Cardiovascular Diseases; Cholesterol, LDL; Cost-Benefit Analysis; Drug Costs; Economics, Pharmaceutical; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Pravastatin; Pyrimidines; Pyrroles; Retrospective Studies; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2005 |
Impact of statins in microalbuminuric subjects with the metabolic syndrome: a substudy of the PREVEND Intervention Trial.
Topics: Albuminuria; Antihypertensive Agents; Cardiovascular Diseases; Coronary Disease; Double-Blind Method; Female; Fosinopril; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Metabolic Syndrome; Middle Aged; Pravastatin; Survival Analysis | 2005 |
Effect of pravastatin in people with diabetes and chronic kidney disease.
Topics: Adult; Age Distribution; Aged; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pravastatin; Prevalence; Probability; Prognosis; Renal Insufficiency, Chronic; Risk Assessment; Sex Distribution; Treatment Outcome | 2005 |
Plasma lipoproteins and apolipoproteins as predictors of cardiovascular risk and treatment benefit in the PROspective Study of Pravastatin in the Elderly at Risk (PROSPER).
Topics: Aged; Aged, 80 and over; Apolipoproteins; Biomarkers; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Lipoproteins; Pravastatin; Risk Assessment | 2005 |
Low-density lipoprotein receptor genotype and response to pravastatin in children with familial hypercholesterolemia: substudy of an intima-media thickness trial.
Topics: Adolescent; Cardiovascular Diseases; Child; Coronary Vessels; Double-Blind Method; Female; Gene Deletion; Genotype; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Male; Placebos; Pravastatin; Receptors, LDL; Tunica Intima; Tunica Media | 2005 |
Effect of pravastatin on body composition and markers of cardiovascular disease in HIV-infected men--a randomized, placebo-controlled study.
Topics: Adipose Tissue; Antiretroviral Therapy, Highly Active; Biomarkers; Blood Glucose; Body Composition; Cardiovascular Diseases; Cholesterol; Diet; Double-Blind Method; HIV Infections; HIV Protease Inhibitors; HIV-Associated Lipodystrophy Syndrome; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Insulin; Male; Middle Aged; Pilot Projects; Pravastatin; Triglycerides | 2006 |
Effect of probucol on elderly hypercholesterolemic patients in the FAST study.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Anticholesteremic Agents; Atherosclerosis; Cardiovascular Diseases; Carotid Arteries; Carotid Artery Diseases; Cohort Studies; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Incidence; Male; Middle Aged; Pravastatin; Probucol; Risk; Treatment Outcome | 2006 |
Effect of pravastatin on blood pressure in people with cardiovascular disease.
Topics: Adult; Aged; Antihypertensive Agents; Blood Pressure; Cardiovascular Diseases; Double-Blind Method; Female; Humans; Male; Middle Aged; Pravastatin; Risk Factors | 2006 |
Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): a prospective randomised controlled trial.
Topics: Adult; Aged; Anticholesteremic Agents; Cardiovascular Diseases; Diet, Fat-Restricted; Female; Follow-Up Studies; Humans; Hypercholesterolemia; Japan; Male; Middle Aged; Pravastatin | 2006 |
C-reactive protein and prediction of coronary heart disease and global vascular events in the Prospective Study of Pravastatin in the Elderly at Risk (PROSPER).
Topics: Aged; Aged, 80 and over; C-Reactive Protein; Cardiovascular Diseases; Coronary Disease; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Pravastatin; Prospective Studies; Risk Factors | 2007 |
Primary prevention of cardiovascular diseases among hypercholesterolemic Japanese with a low dose of pravastatin.
Topics: Adult; Aged; Cardiovascular Diseases; Cholesterol; Cholesterol, LDL; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Incidence; Japan; Male; Middle Aged; Patient Selection; Practice Guidelines as Topic; Pravastatin; Prospective Studies; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome | 2007 |
Lack of evidence of a clopidogrel-statin interaction in the CHARISMA trial.
Topics: Atorvastatin; Cardiovascular Diseases; Clopidogrel; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Double-Blind Method; Drug Interactions; Drug Therapy, Combination; Female; Follow-Up Studies; Hemorrhage; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Platelet Aggregation Inhibitors; Pravastatin; Prospective Studies; Pyrroles; Ticlopidine | 2007 |
Effect of withdrawal of pravastatin therapy on C-reactive protein and low-density lipoprotein cholesterol.
Topics: C-Reactive Protein; Cardiovascular Diseases; Cholesterol, LDL; Double-Blind Method; Female; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pravastatin; Prospective Studies | 2007 |
Usefulness of pravastatin in primary prevention of cardiovascular events in women: analysis of the Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese (MEGA study).
Topics: Adult; Age Factors; Aged; Cardiovascular Diseases; Cerebral Infarction; Coronary Artery Disease; Diet Therapy; Disease Management; Female; Humans; Hypercholesterolemia; Incidence; Japan; Lipids; Male; Middle Aged; Pravastatin; Sex Factors | 2008 |
Genetic variation at the LDL receptor and HMG-CoA reductase gene loci, lipid levels, statin response, and cardiovascular disease incidence in PROSPER.
Topics: Aged; Aged, 80 and over; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Female; Genetic Predisposition to Disease; Humans; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Polymorphism, Single Nucleotide; Pravastatin; Receptors, LDL; Risk Factors; Triglycerides | 2008 |
Reduction in blood pressure with statins: results from the UCSD Statin Study, a randomized trial.
Topics: Antihypertensive Agents; Blood Pressure; Cardiovascular Diseases; Diastole; Double-Blind Method; Female; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Male; Pravastatin; Simvastatin; Stroke; Systole; Treatment Outcome | 2008 |
Effects of pravastatin in patients with serum total cholesterol levels from 5.2 to 7.8 mmol/liter (200 to 300 mg/dl) plus two additional atherosclerotic risk factors. The Pravastatin Multinational Study Group for Cardiac Risk Patients.
Topics: Adult; Aged; Aged, 80 and over; Angina Pectoris; Cardiovascular Diseases; Double-Blind Method; Female; Humans; Hypercholesterolemia; Hypertension; Life Tables; Male; Middle Aged; Myocardial Infarction; Pravastatin; Risk Factors; Smoking; Treatment Outcome | 1993 |
[A new study on hypercholesterolemia. Statin is effective against heart disease].
Topics: Anticholesteremic Agents; Cardiovascular Diseases; Coronary Disease; Humans; Lovastatin; Male; Middle Aged; Pravastatin; Scandinavian and Nordic Countries; Scotland; Simvastatin | 1996 |
Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels.
Topics: Adult; Aged; Anticholesteremic Agents; Cardiovascular Diseases; Coronary Disease; Double-Blind Method; Female; Humans; Incidence; Lipids; Male; Middle Aged; Mortality; Myocardial Infarction; Pravastatin; Risk | 1998 |
Effect of pravastatin on cardiovascular events in older patients with myocardial infarction and cholesterol levels in the average range. Results of the Cholesterol and Recurrent Events (CARE) trial.
Topics: Aged; Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol; Cholesterol, LDL; Double-Blind Method; Female; Humans; Male; Myocardial Infarction; Pravastatin; Recurrence; Statistics as Topic | 1998 |
Rationale, design, and baseline characteristics of a trial of prevention of cardiovascular and renal disease with fosinopril and pravastatin in nonhypertensive, nonhypercholesterolemic subjects with microalbuminuria (the Prevention of REnal and Vascular E
Topics: Adult; Aged; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; Cardiovascular Diseases; Double-Blind Method; Drug Therapy, Combination; Female; Fosinopril; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Kidney Diseases; Male; Middle Aged; Pravastatin; Randomized Controlled Trials as Topic; Research Design | 2000 |
Blood rheology, cardiovascular risk factors, and cardiovascular disease: the West of Scotland Coronary Prevention Study.
Topics: Anticholesteremic Agents; Blood Viscosity; Cardiovascular Diseases; Humans; Lipoproteins; Male; Middle Aged; Pravastatin; Prospective Studies; Risk Factors; Scotland | 2000 |
Statins and cardiovascular diseases: the multiple effects of lipid-lowering therapy by statins.
Topics: Anticholesteremic Agents; Blood Coagulation; Cardiovascular Diseases; Cell Adhesion Molecules; Endothelium, Vascular; Humans; Hypercholesterolemia; Middle Aged; Pravastatin; Simvastatin; Solubility; Vasomotor System | 2000 |
Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study.
Topics: Adult; Aged; Anti-Inflammatory Agents; Anticholesteremic Agents; C-Reactive Protein; Cardiovascular Diseases; Cholesterol, LDL; Cohort Studies; Double-Blind Method; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Linear Models; Male; Middle Aged; Pravastatin | 2001 |
A comparison of low versus standard dose pravastatin therapy for the prevention of cardiovascular events in the elderly: the pravastatin anti-atherosclerosis trial in the elderly (PATE).
Topics: Aged; Aged, 80 and over; Anticholesteremic Agents; Arteriosclerosis; Cardiovascular Diseases; Cholesterol; Diabetes Complications; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Pravastatin; Prospective Studies; Risk Factors; Safety; Triglycerides | 2001 |
Effects of pravastatin on exercise electrocardiography test performance and cardiovascular mortality and morbidity in patients with hypercholesterolemia: Lipid Intervention Study in Kyoto.
Topics: Adult; Anticholesteremic Agents; Apolipoproteins; Body Constitution; Cardiovascular Diseases; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Electrocardiography; Exercise Test; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Japan; Male; Middle Aged; Morbidity; Pravastatin; Predictive Value of Tests; Time Factors; Triglycerides | 2002 |
Rationale and design of a secondary prevention trial of lowering normal plasma cholesterol levels after acute myocardial infarction: the Cholesterol and Recurrent Events trial (CARE)
Topics: Adult; Aged; Algorithms; Cardiovascular Diseases; Cholesterol; Female; Humans; Male; Middle Aged; Myocardial Infarction; Pravastatin; Recurrence; Research Design; Treatment Outcome | 1991 |
102 other study(ies) available for pravastatin and Cardiovascular Diseases
| Article | Year |
|---|---|
Statins No Longer Contraindicated in Pregnancy.
Topics: Atorvastatin; Cardiovascular Diseases; Contraindications; Drug Approval; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pravastatin; Pregnancy; United States; United States Food and Drug Administration | 2021 |
Long-term outcomes of statin dose, class, and use intensity on primary prevention of cardiovascular mortality: a national T2DM cohort study.
Topics: Atorvastatin; Cardiovascular Diseases; Cohort Studies; Diabetes Mellitus, Type 2; Fluvastatin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Pravastatin; Primary Prevention; Rosuvastatin Calcium; Simvastatin | 2023 |
Method development for quantitative determination of seven statins including four active metabolites by means of high-resolution tandem mass spectrometry applicable for adherence testing and therapeutic drug monitoring.
Topics: Atorvastatin; Cardiovascular Diseases; Chromatography, High Pressure Liquid; Drug Monitoring; Guidelines as Topic; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Limit of Detection; Lovastatin; Medication Adherence; Pravastatin; Quality Control; Reference Standards; Tandem Mass Spectrometry | 2020 |
Statins Reverse Postpartum Cardiovascular Dysfunction in a Rat Model of Preeclampsia.
Topics: Animals; Cardiac Output; Cardiovascular Diseases; Disease Models, Animal; Female; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Postpartum Period; Pravastatin; Pre-Eclampsia; Pregnancy; Rats; Rats, Sprague-Dawley; Ventricular Remodeling | 2020 |
Primary Prevention of Cardiocerebrovascular Diseases and Related Deaths According to Statin Type.
Topics: Adult; Aged; Atorvastatin; Cardiovascular Diseases; Cerebrovascular Disorders; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Pravastatin; Primary Prevention; Pyrroles; Quinolines; Retrospective Studies; Rosuvastatin Calcium; Simvastatin | 2020 |
Should This Patient Receive Aspirin?: Grand Rounds Discussion From Beth Israel Deaconess Medical Center.
Topics: Anticholesteremic Agents; Aspirin; Cardiovascular Diseases; Gastrointestinal Hemorrhage; Humans; Hypercholesterolemia; Male; Middle Aged; Platelet Aggregation Inhibitors; Pravastatin; Primary Prevention; Risk Assessment | 2017 |
Pravastatin therapy during preeclampsia prevents long-term adverse health effects in mice.
Topics: Animals; Cardiovascular Diseases; Disease Models, Animal; Endothelin-1; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Male; Mice; Mice, Inbred C57BL; Placenta; Pravastatin; Pre-Eclampsia; Pregnancy; Risk Factors; Vascular Remodeling | 2018 |
Finding the Balance Between Benefits and Harms When Using Statins for Primary Prevention of Cardiovascular Disease: A Modeling Study.
Topics: Adult; Age Factors; Aged; Atorvastatin; Cardiovascular Diseases; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Middle Aged; Pravastatin; Primary Prevention; Risk Assessment; Rosuvastatin Calcium; Sex Factors; Simvastatin | 2019 |
Factors associated with statin selection among privately insured commercial and Medicare patients.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Atorvastatin; Cardiovascular Diseases; Cohort Studies; Comorbidity; Drug Interactions; Dyslipidemias; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Insurance, Health; Male; Medicare; Middle Aged; Pravastatin; Pyrimidines; Pyrroles; Retrospective Studies; Rosuvastatin Calcium; Sex Factors; Simvastatin; Sulfonamides; United States; Young Adult | 2013 |
Long-term statin administration to dams on high-fat diet protects not only them but also their offspring from cardiovascular risk.
Topics: Animals; C-Reactive Protein; Cardiovascular Diseases; Diet, High-Fat; Female; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypertension; Kidney; Lactation; Lipids; Male; Maternal Nutritional Physiological Phenomena; Mice; Mice, Inbred C57BL; Pravastatin; Pregnancy; Prenatal Exposure Delayed Effects; Random Allocation; Weaning | 2013 |
Risk of incident diabetes among patients treated with statins: population based study.
Topics: Aged; Atorvastatin; Cardiovascular Diseases; Cohort Studies; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Dyslipidemias; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Male; Odds Ratio; Ontario; Population Surveillance; Pravastatin; Proportional Hazards Models; Pyrimidines; Pyrroles; Retrospective Studies; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome | 2013 |
[The fixed combination of pravastatin and fenofibrate: what can it provide?].
Topics: Atherosclerosis; Cardiovascular Diseases; Drug Combinations; Dyslipidemias; Fenofibrate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type V; Hypolipidemic Agents; Pravastatin; Risk Factors | 2014 |
[Efficacy studies].
Topics: Cardiovascular Diseases; Cholesterol, HDL; Drug Combinations; Dyslipidemias; Fenofibrate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertriglyceridemia; Hypolipidemic Agents; Lipids; Pravastatin; Risk Factors | 2014 |
[Achievement of therapeutic objectives].
Topics: Atherosclerosis; Cardiovascular Diseases; Drug Administration Schedule; Drug Combinations; Dyslipidemias; Fenofibrate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Medication Adherence; Pravastatin; Risk Factors | 2014 |
[Indications for the combination of pravastatin and fenofibrate according to the type of dyslipidemia].
Topics: Cardiovascular Diseases; Drug Combinations; Dyslipidemias; Fenofibrate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Lipids; Pravastatin; Risk Factors | 2014 |
[Indications for the combination of pravastatin and fenofibrate according to the cardiovascular risk level. Common clinical situations].
Topics: Cardiovascular Diseases; Drug Therapy, Combination; Dyslipidemias; Fenofibrate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Lipids; Pravastatin; Risk Factors | 2014 |
Do statins have a specific drug effect beyond low-density lipoprotein-cholesterol-lowering in the secondary prevention of coronary artery disease?
Topics: Atorvastatin; Cardiovascular Diseases; Female; Humans; Hypercholesterolemia; Male; Myocardial Infarction; Pravastatin | 2015 |
JAAD grand rounds. A patient with cardiovascular disease and widespread scaly plaques.
Topics: Aged; Anticholesteremic Agents; Basement Membrane; Cardiovascular Diseases; Diagnosis, Differential; Drug Eruptions; Humans; Lupus Erythematosus, Cutaneous; Male; Pravastatin; Prostatic Hyperplasia; Pruritus; Skin | 2015 |
A population-based analysis of the risk of drug interaction between clarithromycin and statins for hospitalisation or death.
Topics: Adult; Aged; Atorvastatin; Cardiovascular Diseases; Clarithromycin; Cytochrome P-450 CYP3A Inhibitors; Drug Interactions; Dyslipidemias; Female; Hospitalization; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pravastatin; Retrospective Studies; Risk; Rosuvastatin Calcium; Simvastatin | 2015 |
Lipid-lowering treatment patterns in patients with new cardiovascular events - estimates from population-based register data in Sweden.
Topics: Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Female; Humans; Hyperlipidemias; Male; Middle Aged; Pravastatin; Retrospective Studies; Risk Factors; Simvastatin; Sweden | 2016 |
Long-Term Safety and Efficacy of Lowering Low-Density Lipoprotein Cholesterol With Statin Therapy: 20-Year Follow-Up of West of Scotland Coronary Prevention Study.
Topics: Cardiovascular Diseases; Cause of Death; Cholesterol, LDL; Diabetes Complications; Diabetes Mellitus; Follow-Up Studies; Hospitalization; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Mortality; Neoplasms; Pravastatin; Proportional Hazards Models; Randomized Controlled Trials as Topic; Scotland; Survival Analysis | 2016 |
Regression Discontinuity Design: Simulation and Application in Two Cardiovascular Trials with Continuous Outcomes.
Topics: Aged; Aged, 80 and over; Blood Pressure; Cardiovascular Diseases; Cholesterol; Computer Simulation; Coronary Disease; Dementia; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Linear Models; Male; Monte Carlo Method; Pravastatin; Randomized Controlled Trials as Topic; Regression Analysis; Reproducibility of Results; Research Design; Risk Reduction Behavior; Statistics as Topic | 2016 |
Lack of effects of statins on high-density lipoprotein subfractions in HIV-1-infected patients receiving protease inhibitors.
Topics: Adult; Cardiovascular Diseases; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipoproteins, HDL; Male; Middle Aged; Pravastatin; Risk; Rosuvastatin Calcium | 2017 |
Intensive statin regimens for reducing risk of cardiovascular diseases among human immunodeficiency virus-infected population: A nation-wide longitudinal cohort study 2000-2011.
Topics: Adult; Cardiovascular Diseases; Dose-Response Relationship, Drug; Female; Follow-Up Studies; HIV; HIV Infections; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Male; Middle Aged; Population Surveillance; Pravastatin; Retrospective Studies; Risk Assessment; Risk Factors; Taiwan; Treatment Outcome; Young Adult | 2017 |
Pravastatin reduces the risk for cardiovascular disease in Japanese hypercholesterolemic patients with impaired fasting glucose or diabetes: diabetes subanalysis of the Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese (
Topics: Adult; Cardiovascular Diseases; Cholesterol; Diabetes Mellitus; Fasting; Female; Glucose; Humans; Hypercholesterolemia; Japan; Lipids; Male; Middle Aged; Pravastatin; Risk | 2008 |
Reduced glomerular filtration rate and its association with clinical outcome in older patients at risk of vascular events: secondary analysis.
Topics: Aged; Aged, 80 and over; Cardiovascular Diseases; Female; Glomerular Filtration Rate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney Diseases; Male; Pravastatin; Prospective Studies; Risk Factors; Treatment Outcome; Vascular Diseases | 2009 |
[Comment from the cardiologic viewpoint].
Topics: Atorvastatin; C-Reactive Protein; Cardiovascular Diseases; Cholesterol, LDL; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Male; Pravastatin; Primary Prevention; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Risk Factors; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2009 |
Rosuvastatin in patients with elevated C-reactive protein.
Topics: Cardiovascular Diseases; Diabetes Mellitus; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pravastatin; Pyrimidines; Risk; Rosuvastatin Calcium; Sulfonamides | 2009 |
Effects of statins on the secretion of human serum albumin in cultured HepG2 cells.
Topics: Cardiovascular Diseases; Cell Line; Dose-Response Relationship, Drug; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Pravastatin; Serum Albumin; Simvastatin | 2009 |
Chronic treatment with pravastatin prevents early cardiovascular changes in spontaneously hypertensive rats.
Topics: Animals; Blood Pressure; Cardiovascular Diseases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Hypertrophy, Left Ventricular; Lipid Peroxidation; Male; Nitric Oxide; Nitroprusside; Oxidative Stress; Phenylephrine; Pravastatin; Rats; Rats, Inbred SHR; Superoxides | 2009 |
Rosuvastatin for cardiovascular prevention: too many uncertainties.
Topics: Aged; Angina, Unstable; Anticholesteremic Agents; Cardiovascular Diseases; Diabetes Mellitus; Double-Blind Method; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Myocardial Infarction; Myocardial Revascularization; Pravastatin; Pyrimidines; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Simvastatin; Stroke; Sulfonamides; Uncertainty | 2009 |
Prevention of contrast-induced nephropathy by chronic pravastatin treatment in patients with cardiovascular disease and renal insufficiency.
Topics: Aged; Angioplasty; Biomarkers; Cardiovascular Diseases; Contrast Media; Coronary Angiography; Creatinine; Diabetes Mellitus; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney Diseases; Logistic Models; Male; Middle Aged; Pravastatin; Renal Insufficiency; Risk Factors | 2009 |
Does higher usage of low-cost statins correlate with a poorer achievement in cholesterol quality markers for secondary prevention?
Topics: Cardiovascular Diseases; Drug Costs; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Outcome and Process Assessment, Health Care; Pravastatin; Secondary Prevention; Simvastatin; Stroke | 2010 |
Cardiovascular outcomes in randomized trials: should time to first event for "hard" end points remain the standard approach?
Topics: Atorvastatin; Cardiovascular Diseases; Cholesterol; Endpoint Determination; Heptanoic Acids; Hospitalization; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Revascularization; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Secondary Prevention; Stroke; Time Factors | 2009 |
High-sensitivity C-reactive protein levels fall during statin therapy in HIV-infected patients receiving ritonavir-boosted protease inhibitors.
Topics: Anticholesteremic Agents; C-Reactive Protein; Cardiovascular Diseases; Cholesterol, LDL; Dyslipidemias; Female; HIV Infections; Humans; Male; Middle Aged; Pravastatin; Ritonavir | 2011 |
Rosuvastatin and primary cardiovascular prevention. Continue to use pravastatin or simvastatin.
Topics: Anticholesteremic Agents; Cardiovascular Diseases; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pravastatin; Primary Prevention; Pyrimidines; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2011 |
High-sensitivity C-reactive protein levels do not decrease with the use of statins in all persons with HIV infection.
Topics: C-Reactive Protein; Cardiovascular Diseases; Dyslipidemias; Female; HIV Infections; Humans; Male; Pravastatin; Ritonavir | 2011 |
[Achievement of therapeutic target in subjects on statin treatment in clinical practice. Results of the STAR (Statins Target Assessment in Real practice) study].
Topics: Aged; Algorithms; Azetidines; Biomarkers; Cardiovascular Diseases; Cerebrovascular Disorders; Cholesterol, LDL; Cohort Studies; Diabetes Complications; Diabetes Mellitus; Ezetimibe; Female; Fluorobenzenes; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Italy; Lovastatin; Male; Medication Adherence; Middle Aged; Pravastatin; Pyrimidines; Retrospective Studies; Risk Assessment; Risk Factors; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome | 2011 |
Cholesterol level goal attainment with statins: clinical management guideline recommendations versus management in actual clinical practice.
Topics: Aged; Atorvastatin; Cardiovascular Diseases; Cholesterol; Cohort Studies; Databases, Factual; Dose-Response Relationship, Drug; Female; Fluorobenzenes; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Medication Adherence; Middle Aged; Netherlands; Practice Guidelines as Topic; Pravastatin; Pyrimidines; Pyrroles; Retrospective Studies; Risk; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2012 |
N-terminal pro-B-type natriuretic peptide and the prediction of primary cardiovascular events: results from 15-year follow-up of WOSCOPS.
Topics: Biomarkers; C-Reactive Protein; Cardiovascular Diseases; Electrocardiography; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Natriuretic Peptide, Brain; Peptide Fragments; Pravastatin; Randomized Controlled Trials as Topic; Risk Factors; Scotland | 2013 |
Risk reductions for cardiovascular disease with pravastatin treatment by dyslipidemia phenotype: a post hoc analysis of the MEGA Study.
Topics: Adult; Aged; Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol, HDL; Dyslipidemias; Electrophoresis; Female; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Phenotype; Pravastatin; Randomized Controlled Trials as Topic; Regression Analysis; Risk Reduction Behavior; Time Factors | 2013 |
Pravastatin and Aspirin.
Topics: Advisory Committees; Aspirin; Cardiovascular Agents; Cardiovascular Diseases; Drug Packaging; Drug Therapy, Combination; Humans; Hypertension; Pravastatin | 2002 |
High-risk elderly patients PROSPER from cholesterol-lowering therapy.
Topics: Aged; Aged, 80 and over; Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol, LDL; Clinical Trials as Topic; Humans; Pravastatin; Risk Factors | 2002 |
The ALLHAT lipid lowering trial--less is less.
Topics: Anticholesteremic Agents; Cardiovascular Diseases; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypertension; Pravastatin | 2002 |
Measuring the cost-effectiveness of lipid-lowering drugs in the elderly: the outcomes research and economic analysis components of the PROSPER trial.
Topics: Aged; Aged, 80 and over; Anticholesteremic Agents; Cardiovascular Diseases; Cost-Benefit Analysis; Direct Service Costs; Female; Humans; Ireland; Life Tables; Male; Markov Chains; Multicenter Studies as Topic; Netherlands; Pravastatin; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Risk; Scotland; Software Design | 2002 |
[Treatment with statins: further data from the Heart Protection Study].
Topics: Adult; Aged; Anticholesteremic Agents; Cardiovascular Diseases; Coronary Disease; Diabetes Mellitus; Female; Humans; Lovastatin; Male; Meta-Analysis as Topic; Middle Aged; Pravastatin; Primary Prevention; Risk Factors; Simvastatin | 2002 |
Summaries for patients. Treating cholesterol in patients with mild kidney disease.
Topics: Aged; Cardiovascular Diseases; Double-Blind Method; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Kidney Failure, Chronic; Male; Middle Aged; Pravastatin | 2003 |
The PROSPER trial.
Topics: Aged; Anticholesteremic Agents; Biomarkers; C-Reactive Protein; Cardiovascular Diseases; Cholesterol, LDL; Humans; Inflammation; Patient Selection; Pravastatin; Predictive Value of Tests; Primary Prevention; Risk Factors | 2003 |
The PROSPER trial.
Topics: Age Factors; Aged; Anticholesteremic Agents; Cardiovascular Diseases; Humans; Patient Selection; Pravastatin | 2003 |
Allocating funds for cardiovascular disease prevention in light of the NCEP ATP III guidelines.
Topics: Adult; Anticholesteremic Agents; Canada; Cardiovascular Diseases; Cost of Illness; Cost Savings; Female; Health Care Rationing; Health Expenditures; Health Policy; Health Services Research; Health Status Indicators; Humans; Male; Practice Guidelines as Topic; Pravastatin; Preventive Health Services; Quality-Adjusted Life Years; Risk Factors | 2003 |
A polymorphism of the cholesteryl ester transfer protein gene predicts cardiovascular events in non-smokers in the West of Scotland Coronary Prevention Study.
Topics: Aged; Anticholesteremic Agents; Cardiovascular Diseases; Carrier Proteins; Cholesterol Ester Transfer Proteins; Coronary Disease; Genotype; Glycoproteins; Homozygote; Humans; Male; Middle Aged; Multivariate Analysis; Polymorphism, Genetic; Pravastatin; Risk Factors; Scotland; Smoking | 2003 |
Accuracy of the Australian National Death Index: comparison with adjudicated fatal outcomes among Australian participants in the Long-term Intervention with Pravastatin in Ischaemic Disease (LIPID) study.
Topics: Adult; Aged; Anticholesteremic Agents; Australia; Cardiovascular Diseases; Causality; Cohort Studies; Humans; Middle Aged; Mortality; Neoplasms; New Zealand; Pravastatin; Randomized Controlled Trials as Topic; Registries; Reproducibility of Results; Time | 2003 |
Intensive statin therapy--a sea change in cardiovascular prevention.
Topics: Angina, Unstable; Atorvastatin; C-Reactive Protein; Cardiovascular Diseases; Cholesterol, LDL; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Infarction; Pravastatin; Pyrroles | 2004 |
C-reactive protein is not only an inflammatory marker but also a direct cause of cardiovascular diseases.
Topics: Acute-Phase Reaction; Aspirin; Atorvastatin; Biomarkers; C-Reactive Protein; Cardiovascular Diseases; Clinical Trials as Topic; Coronary Artery Disease; Heptanoic Acids; Humans; Incidence; Inflammation; Interleukin-6; Lovastatin; Pravastatin; Predictive Value of Tests; Pyrroles; Risk Factors; Simvastatin | 2004 |
Battle of the statins, or how the news media can change patient care.
Topics: Atorvastatin; Cardiovascular Diseases; Coronary Disease; Evidence-Based Medicine; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Mass Media; Practice Patterns, Physicians'; Pravastatin; Pyrroles | 2004 |
Intensive versus moderate lipid lowering with statins after acute coronary syndromes.
Topics: Angina, Unstable; Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Infarction; Patient Dropouts; Pravastatin; Pyrroles | 2004 |
Intensive versus moderate lipid lowering with statins after acute coronary syndromes.
Topics: Angina, Unstable; Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Cholesterol, LDL; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Infarction; Pravastatin; Pyrroles | 2004 |
Intensive versus moderate lipid lowering with statins after acute coronary syndromes.
Topics: Angina, Unstable; Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Infarction; Pravastatin; Pyrroles; Triglycerides | 2004 |
[Statin therapy in patients with acute coronary syndrome. "Prove-it" study].
Topics: Angina, Unstable; Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Double-Blind Method; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Pravastatin; Proportional Hazards Models; Pyrroles; Randomized Controlled Trials as Topic; Syndrome; Treatment Outcome | 2004 |
Lessons from the PROVE-IT trial. Higher dose of potent statin better for high-risk patients.
Topics: Cardiovascular Diseases; Cholesterol, LDL; Dose-Response Relationship, Drug; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Pravastatin; Randomized Controlled Trials as Topic | 2004 |
Plasma lipoprotein(a) [Lp(a)] concentrations and cardiovascular events in the elderly: evidence from the prospective study of pravastatin in the elderly at risk (PROSPER).
Topics: Aged; Aged, 80 and over; Aging; Anticholesteremic Agents; Cardiovascular Diseases; Cognition Disorders; Cohort Studies; Disabled Persons; Female; Humans; Lipoprotein(a); Male; Pravastatin; Predictive Value of Tests; Risk Factors | 2005 |
Relation of diet to cardiovascular disease risk factors in subjects with cardiovascular disease in Australia and New Zealand: analysis of the Long-Term Intervention with Pravastatin in Ischaemic Disease trial.
Topics: Aged; Alcohol Drinking; Anticholesteremic Agents; Australia; Cardiovascular Diseases; Cholesterol, Dietary; Cholesterol, HDL; Cholesterol, LDL; Cohort Studies; Diet; Diet Surveys; Dietary Fats; Epidemiologic Factors; Female; Humans; Male; Middle Aged; New Zealand; Pravastatin; Risk Factors; Surveys and Questionnaires; Triglycerides | 2005 |
Intensive lipid lowering with atorvastatin in coronary disease.
Topics: Atorvastatin; Cardiovascular Diseases; Coronary Disease; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pravastatin; Pyrroles; Risk | 2005 |
[Intensive LDL lowering to under 80 mg/dl: hypercholesteremia patients with stable coronary disease and diabetes profit especially significantly].
Topics: Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Cholesterol, LDL; Clinical Trials as Topic; Coronary Disease; Diabetes Complications; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Life Expectancy; Pravastatin; Pyrroles; Risk; Risk Factors; Time Factors | 2005 |
Differences between statins on clinical endpoints: a population-based cohort study.
Topics: Adult; Aged; Atorvastatin; Cardiovascular Diseases; Cholesterol; Cohort Studies; Endpoint Determination; Family Practice; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Male; Middle Aged; Netherlands; Pravastatin; Pyridines; Pyrroles; Simvastatin; Treatment Outcome | 2005 |
Neither plasma coenzyme Q10 concentration, nor its decline during pravastatin therapy, is linked to recurrent cardiovascular disease events: a prospective case-control study from the LIPID study.
Topics: Cardiovascular Diseases; Case-Control Studies; Coenzymes; Dose-Response Relationship, Drug; Fatty Acids, Unsaturated; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Placebos; Pravastatin; Prospective Studies; Recurrence; Regression Analysis; Risk; Ubiquinone | 2006 |
Low high-density lipoprotein cholesterol and cardiovascular disease: risk reduction with statin therapy.
Topics: Atorvastatin; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Coronary Artery Disease; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Particle Size; Polymorphism, Genetic; Pravastatin; Pyrroles; Risk Factors; Simvastatin | 2006 |
A tale of two trials: a comparison of the post-acute coronary syndrome lipid-lowering trials A to Z and PROVE IT-TIMI 22.
Topics: Aged; Angina, Unstable; Atorvastatin; C-Reactive Protein; Cardiovascular Diseases; Case Management; Chemical and Drug Induced Liver Injury; Comorbidity; Confounding Factors, Epidemiologic; Dose-Response Relationship, Drug; Endpoint Determination; Female; Heptanoic Acids; Hospitalization; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Life Tables; Lipids; Male; Middle Aged; Multicenter Studies as Topic; Myocardial Infarction; Myocardial Ischemia; Myocardial Revascularization; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Research Design; Risk; Risk Factors; Simvastatin; Stroke; Tirofiban; Treatment Outcome; Tyrosine | 2006 |
Statins in HIV-associated lipodystrophy and metabolic syndrome: is there a missing link?
Topics: Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol; HIV Infections; HIV Protease Inhibitors; HIV-Associated Lipodystrophy Syndrome; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Metabolic Syndrome; Pravastatin; Treatment Outcome | 2006 |
Cost-effectiveness of screening for albuminuria with subsequent fosinopril treatment to prevent cardiovascular events: A pharmacoeconomic analysis linked to the prevention of renal and vascular endstage disease (PREVEND) study and the prevention of renal
Topics: Adult; Aged; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Cardiovascular Diseases; Cost-Benefit Analysis; Female; Fosinopril; Health Care Costs; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Male; Mass Screening; Middle Aged; Netherlands; Pravastatin; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic | 2006 |
Plasma cholesteryl ester transfer protein concentrations predict cardiovascular events in patients with coronary artery disease treated with pravastatin.
Topics: Adult; Aged; Analysis of Variance; Anticholesteremic Agents; Biomarkers; Cardiovascular Diseases; Carrier Proteins; Cholesterol Ester Transfer Proteins; Cholesterol, LDL; Coronary Artery Disease; Female; Genetic Markers; Genotype; Glycoproteins; Humans; Hypercholesterolemia; Male; Middle Aged; Polymorphism, Restriction Fragment Length; Pravastatin; Prospective Studies | 2006 |
Multitherapy for diabetes.
Topics: Bezafibrate; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Dyslipidemias; Humans; Hypolipidemic Agents; Pravastatin | 2006 |
The MEGA study.
Topics: Cardiovascular Diseases; Diet; Female; Humans; Hypercholesterolemia; Japan; Myocardial Revascularization; Pravastatin; Research Design | 2006 |
Cholesterol lowering with statins: how WOSCOPS confounded the skeptics.
Topics: Cardiovascular Diseases; Cholesterol; Cohort Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Practice Guidelines as Topic; Pravastatin; Randomized Controlled Trials as Topic; Research Design; Risk Assessment; Risk Factors; Scotland; Time Factors; Treatment Outcome | 2007 |
Cardiovascular health in New Zealand: areas of concern and targets for improvement in 2008 and beyond.
Topics: Australia; Cardiovascular Diseases; Drug Costs; Health Priorities; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; New Zealand; Pravastatin; Risk Factors | 2008 |
Differences in cardiovascular mortality between Australia and New Zealand according to socioeconomic status: findings from the Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study.
Topics: Adult; Aged; Australia; Cardiovascular Diseases; Chi-Square Distribution; Female; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Income; Linear Models; Male; Middle Aged; New Zealand; Pravastatin; Risk Factors; Severity of Illness Index; Social Class | 2008 |
The Food and Drug Administration and over-the-counter statins: an opportunity lost?
Topics: Adult; Aged; Cardiovascular Diseases; Contraindications; Drug Approval; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipoproteins, LDL; Lovastatin; Male; Middle Aged; Nonprescription Drugs; Pravastatin; Pregnancy; Self Administration; United States; United States Food and Drug Administration | 2008 |
Lipid levels and low-density lipoprotein cholesterol goal attainment in diabetic patients: rosuvastatin compared with other statins in usual care.
Topics: Adult; Aged; Atorvastatin; Cardiovascular Diseases; Cholesterol, LDL; Cohort Studies; Diabetes Complications; Fatty Acids, Monounsaturated; Female; Fluorobenzenes; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Male; Managed Care Programs; Middle Aged; Practice Guidelines as Topic; Pravastatin; Pyrimidines; Pyrroles; Retrospective Studies; Risk Factors; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome; United States | 2008 |
Can metabolic syndrome usefully predict cardiovascular disease and diabetes? Outcome data from two prospective studies.
Topics: Aged; Aged, 80 and over; Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol; Diabetes Mellitus, Type 2; Female; Geriatrics; Humans; Male; Metabolic Syndrome; Middle Aged; Multicenter Studies as Topic; Pravastatin; Predictive Value of Tests; Prospective Studies; Randomized Controlled Trials as Topic; Risk Factors | 2008 |
The rapid reduction in cardiac events with lipid-lowering therapy: mechanisms and implications.
Topics: Cardiovascular Diseases; Humans; Hypercholesterolemia; Pravastatin; Risk Factors | 1993 |
Conference review: scientific session of the American College of Cardiology 1996.
Topics: Amiodarone; Anti-Arrhythmia Agents; Anticholesteremic Agents; Anticoagulants; Biomarkers; Cardiology; Cardiovascular Diseases; Digoxin; Endothelium, Vascular; Humans; Pravastatin; Societies, Medical | 1996 |
Cost effectiveness of lowering cholesterol. Statin treatment should be started early.
Topics: Cardiovascular Diseases; Cost-Benefit Analysis; Fatty Acids, Monounsaturated; Fluvastatin; Humans; Hypercholesterolemia; Indoles; Lovastatin; Pravastatin; Simvastatin | 1996 |
[Assessment of short-term effects of awareness programs and pravastatin therapy on subjects from private clinics at high risk for cardiovascular disease].
Topics: Adult; Aged; Blood Pressure; Body Weight; Cardiovascular Diseases; Cholesterol; Evaluation Studies as Topic; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Pravastatin; Program Evaluation; Risk Factors | 1997 |
Lipid-lowering therapy in low-risk patients.
Topics: Cardiovascular Diseases; Cholesterol, LDL; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Lovastatin; Pravastatin; Risk Factors; Simvastatin | 1998 |
Effects of chronic combined treatment with captopril and pravastatin on the progression of insulin resistance and cardiovascular alterations in an experimental model of obesity in dogs.
Topics: Animals; Anticholesteremic Agents; Antihypertensive Agents; Blood Glucose; Blood Pressure; Body Weight; Captopril; Cardiovascular Diseases; Cholesterol; Coronary Vessels; Disease Models, Animal; Disease Progression; Dogs; Drug Therapy, Combination; Heart; Insulin; Insulin Resistance; Linear Models; Male; Multivariate Analysis; Myocardium; Obesity; Pravastatin; Triglycerides | 1998 |
A simple computer program for guiding management of cardiovascular risk factors and prescribing.
Topics: Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol; Coronary Disease; Female; Humans; Male; Myocardial Infarction; Practice Guidelines as Topic; Practice Patterns, Physicians'; Pravastatin; Risk Assessment; Risk Factors; Smoking; Software | 1999 |
Use of diagnostic cluster methodology for therapeutic costing and drug surveillance of HMG-CoA reductase-inhibitor therapy.
Topics: Cardiovascular Diseases; Cluster Analysis; Costs and Cost Analysis; Databases, Factual; Diagnosis-Related Groups; Female; Health Care Costs; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Male; Medical Audit; Middle Aged; Pravastatin; Product Surveillance, Postmarketing; Registries; Retrospective Studies; Severity of Illness Index; Simvastatin; United States | 1999 |
International economic analysis of primary prevention of cardiovascular disease with pravastatin in WOSCOPS. West of Scotland Coronary Prevention Study.
Topics: Aged; Anticholesteremic Agents; Cardiovascular Diseases; Costs and Cost Analysis; Health Care Costs; Humans; International Cooperation; Male; Middle Aged; Models, Economic; Pravastatin; Primary Prevention; Reproducibility of Results; Sensitivity and Specificity; United Kingdom | 1999 |
Pravastatin and coronary heart disease.
Topics: Anticholesteremic Agents; Cardiovascular Diseases; Coronary Disease; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pravastatin; Treatment Outcome | 1999 |
The change of cost: reference-based pricing and the statins.
Topics: Anticholesteremic Agents; Canada; Cardiovascular Diseases; Drug Costs; Economics, Pharmaceutical; Fatty Acids, Monounsaturated; Fluvastatin; Humans; Indoles; Pravastatin; Simvastatin | 1999 |
Cholesterol lowering in older patients.
Topics: Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol; Humans; Pravastatin | 1999 |
Coverage by the news media of the benefits and risks of medications.
Topics: Alendronate; Anticholesteremic Agents; Aspirin; Biomedical Research; Cardiovascular Diseases; Conflict of Interest; Cost-Benefit Analysis; Disclosure; Drug Therapy; Drug-Related Side Effects and Adverse Reactions; Fees, Pharmaceutical; Humans; Journalism, Medical; Mass Media; Newspapers as Topic; Osteoporosis; Pravastatin; Risk Assessment; Television; United States | 2000 |
RE: M Thomas. The change of cost: reference-based pricing and the statins. 1999;15:535-8.
Topics: Anticholesteremic Agents; Cardiovascular Diseases; Drug Costs; Economics, Pharmaceutical; Humans; Indoles; New Zealand; Pravastatin; Simvastatin | 1999 |
[Socioeconomic aspects of therapy of cardiovascular diseases].
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol; Cholesterol, LDL; Cost-Benefit Analysis; Costs and Cost Analysis; Female; Health Priorities; Humans; Hyperlipidemias; Male; Middle Aged; Pravastatin; Primary Prevention; Prognosis; Risk Factors; Socioeconomic Factors | 2000 |
Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cardiovascular Diseases; Cholesterol; Cross-Sectional Studies; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Hypolipidemic Agents; Lovastatin; Male; Middle Aged; Pravastatin; Prevalence; Retrospective Studies; Risk Factors; Treatment Outcome | 2000 |
A case for lipid-lowering?
Topics: Bezafibrate; Cardiovascular Diseases; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Diabetes Mellitus, Type 2; Gemfibrozil; Humans; Hyperlipidemias; Hypolipidemic Agents; Male; Middle Aged; Pravastatin; Risk Factors; Triglycerides | 2000 |
Placing PRINCE in perspective.
Topics: Anticholesteremic Agents; C-Reactive Protein; Cardiovascular Diseases; Cholesterol, LDL; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pravastatin | 2001 |
Diabetes, statins and cardiovascular disease.
Topics: Anticholesteremic Agents; Cardiovascular Diseases; Diabetes Complications; Diabetic Angiopathies; Humans; Hyperlipidemias; Pravastatin | 2001 |
Hyperlipidaemia and cardiovascular disease.
Topics: Animals; Anticholesteremic Agents; Cardiovascular Diseases; Endothelium, Vascular; Humans; Hyperlipidemias; Lovastatin; Nitric Oxide; Pravastatin; Rabbits; Simvastatin | 2001 |
High-sensitivity C-reactive protein: potential adjunct for global risk assessment in the primary prevention of cardiovascular disease.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Biomarkers; C-Reactive Protein; Cardiovascular Diseases; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Pravastatin; Predictive Value of Tests; Risk Assessment; Sensitivity and Specificity | 2001 |
Assessing the cost-effectiveness of pharmacogenomics.
Topics: Anticholesteremic Agents; Anticoagulants; Antimetabolites, Antineoplastic; Cardiovascular Diseases; Carrier Proteins; Child; Cholesterol Ester Transfer Proteins; Cost-Benefit Analysis; Drug Therapy; Genotype; Glycoproteins; Hepatitis C; Humans; Interferons; Mercaptopurine; Methyltransferases; Pharmacogenetics; Pharmacology, Clinical; Phenotype; Pravastatin; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Ribavirin; Warfarin | 2000 |
Safety and tolerability of pravastatin in long-term clinical trials: prospective Pravastatin Pooling (PPP) Project.
Topics: Aged; Anticholesteremic Agents; Breast Neoplasms; Cardiovascular Diseases; Chemical and Drug Induced Liver Injury; Cohort Studies; Comorbidity; Demography; Double-Blind Method; Female; Gastrointestinal Diseases; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Incidence; Liver Diseases; Male; Middle Aged; Multivariate Analysis; Muscular Diseases; Pravastatin; Proportional Hazards Models; Prospective Studies; Randomized Controlled Trials as Topic; Renal Insufficiency; Risk; Risk Assessment; Time | 2002 |